

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Impact of red and processed meat and fibre intake on risk of chronic inflammatory diseases: a prospective cohort study on prognostic factors using the Danish "Diet, Cancer and Health" cohort (PROCID-DCH): Protocol for a prospective cohort study of prognostic factors and disease risk.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024555
Article Type:	Protocol
Date Submitted by the Author:	01-Jun-2018
Complete List of Authors:	<p>Rasmussen, Nathalie; Aarhus University, Faculty of Health Sciences; Hospital of Southern Jutland, Focused research unit for Molecular Diagnostic and Clinical Research, IRS-Center Sonderjylland</p> <p>Rubin, Katrine; University of Southern Denmark, and Odense University Hospital, Odense, OPEN - Odense Patient data Explorative Network, Department of Clinical Research</p> <p>Stougaard, Maria; University of Southern Denmark, and Odense University Hospital, OPEN - Odense Patient data Explorative Network, Department of Clinical Research</p> <p>Tjønneland, Anne; Institute of Cancer Epidemiology,, Danish Cancer Society</p> <p>Stenager, Egon; University of Southern Denmark, Department of Regional Health Research; Hospital of Southern Jutland, The Multiple Sclerosis Clinic of Southern Jutland (Sonderborg, Kolding, Esbjerg), Department of Neurology</p> <p>Lund Hetland, Merete; Rigshospitalet Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics; The DANBIO registry</p> <p>Glintborg, B.; Gentofte Hospital, Department of Rheumatology; University of Copenhagen, The Parker Institute, Bispebjerg and Frederiksberg Bygum, Anette; Odense Universitetshospital, Department of Dermatology and Allergy Centre</p> <p>Andersen, Vibeke; Hospital of Southern Jutland, Focused research unit for Molecular Diagnostic and Clinical Research; Syddansk Universitet Det Sundhedsvidenskabelige Fakultet, institute og molecular medicine</p>
Keywords:	lifestyle, diet, chronic inflammatory diseases, disease risk, fibre, red meat

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Word count:** 3,450 (excluding title page, abstract, references, figures and tables)

2 **Abbreviated title:** Impact of red and processed meat and fibre on risk of CID

3
4 **Impact of red and processed meat and fibre intake on risk of chronic**
5 **inflammatory diseases: a prospective cohort study on prognostic factors**
6 **using the Danish "Diet, Cancer and Health" cohort (PROCID-DCH):**

7 *Protocol for a prospective cohort study of prognostic factors and disease risk*

8 Nathalie Fogh Rasmussen¹, Katrine Hass Rubin², Maria Stougaard², Anne Tjønneland³, Egon Stenager⁴,
9 Merete Lund Hetland⁵, Bente Glintborg⁶, Anette Bygum⁷, Vibeke Andersen^{8,9,10}

10 ¹Department of Health, Aarhus University, Aarhus, Denmark

11 ²OPEN - Odense Patient data Explorative Network, Department of Clinical Research, University of Southern Denmark,
12 and Odense University Hospital, Odense, Denmark

13 ³Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen Ø, Denmark/Department of Public
14 Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

15 ⁴Department of Regional Health Research, University of Southern Denmark, Odense C, Denmark/The Multiple Sclerosis
16 Clinic of Southern Jutland (Sonderborg, Kolding, Esbjerg), Department of Neurology, Hospital of Southern Jutland,
17 Sonderborg, Denmark

18 ⁵The DANBIO registry/Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine
19 Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark

20 ⁶Department of Rheumatology, Herlev and Gentofte University Hospital, Hellerup, Denmark/The Parker Institute,
21 Bispebjerg and Frederiksberg, University of Copenhagen, Copenhagen, Denmark

22 ⁷Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark

23 ⁸Focused research unit for Molecular Diagnostic and Clinical Research, IRS-Center Sonderjylland, Hospital of Southern
24 Jutland, Aabenraa, Denmark

25 ⁹Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark

26 ¹⁰Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark

27
28
29
30
31
32 **Correspondence:** Vibeke Andersen, Focused Research Unit for Molecular Diagnostic and Clinical Research

33 (MOK), IRS-Center Sonderjylland "Forskningshuset", Hospital of Southern Jutland, Kresten Philipsens Vej

34 15 F, 6200 Aabenraa, Denmark, email: vandersen@health.sdu.dk

1
2
3
4 35 **ABSTRACT**

5
6
7 36 **Introduction:** Chronic inflammatory diseases, CIDs, (Crohn's disease, ulcerative colitis, psoriasis,
8
9 37 psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, or multiple sclerosis) are diseases
10
11 38 of the immune system that have some shared genetic and environmental predisposing factors,
12
13 39 but still few studies have investigated the effects of lifestyle on disease risk of several CIDs. The
14
15 40 primary aim of this prospective cohort study is to investigate the impact of fibre and red and
16
17 41 processed meat on risk of CID, with the perspective that results of this study can contribute in
18
19 42 supporting future diet recommendations for effective personalized prevention.
20
21
22
23

24 43 **Methods and analysis:** The study will use data from 57,053 persons from the prospective Danish
25
26 44 cohort study "Diet, Cancer and Health" (DCH) together with National Health Registry data. The
27
28 45 follow up period is from December 1993 to May 2018. Questionnaire data on diet and lifestyle
29
30 46 were collected at the DCH study entry. The outcome CID is defined as having a diagnosis of one
31
32 47 of the CIDs registered in the National Patient Registry (NPR) or, for multiple sclerosis, in the
33
34 48 Danish Multiple Sclerosis Registry (DMSR) during follow-up AND being treated with a drug
35
36 49 used for the specific disease. The major outcome of the analyses will be to detect variability in risk
37
38 50 of any CID and, if power allows, disease risk of each CID diagnosis between persons with
39
40 51 different fibre and red and processed meat intake. The outcome will be adjusted for age, sex, BMI,
41
42 52 physical activity, alcohol, fermented dairy products, education, smoking status, hormone
43
44 53 replacement therapy, and comorbidity.
45
46
47
48
49

50
51 54 **Trial Registration details:** ClinicalTrials.gov identifier: NCT03456206
52
53

54 55 **Keywords:** lifestyle; diet; chronic inflammatory diseases; disease risk; fibre; red meat
55
56
57
58
59
60

1
2
3
4 56 **Ethics and dissemination:** The study is approved by the Danish Data Protection Agency (2012-58-
5
6 57 0018). The core study is an open register-based cohort study. The study does not need approval
7
8 58 from the Ethics committee or Institutional Review Board by Danish law. Study findings will be
9
10
11 59 disseminated through peer-reviewed journals, patient associations and presentations at
12
13 60 international conferences.
14

Strengths and limitations of this study

Strengths:

- The linkage to Danish national registers will ensure almost complete follow-up of the study population, as the Danish registries are considered of high validity and completeness
- The big sample size will enable a sufficient power of the total CID disease group even when taking loss to emigration and competing risk of death into account
- The study includes several chronic inflammatory diseases

Limitations:

- Risk of low specificity of the diagnostic codes and treatment codes as criteria for identifying CID cases
- Prospective studies including younger age groups are necessary to reveal the generalizability of the results

61

62 INTRODUCTION

63 The CIDs can be considered as systemic diseases which primarily affect one organ such as
64 the intestine (inflammatory bowel disease: Crohn's disease (CD) and colitis ulcerosa (UC)), skin
65 (psoriasis (PsO)), joints (rheumatoid arthritis (RA)/axial spondyloarthritis (AxSpA)/psoriatic
66 arthritis (PsA)), or the brain (multiple sclerosis (MS)).

67 The peak of disease-onset is in the adult phase of life. The diseases have a large impact on the
68 patients and their families' quality of life due to lack of causative treatment, and on the society due
69 to absence from work and on health care economy due to lack of preventative measures.¹⁻⁷ The
70 CIDs have a high prevalence, with inflammatory bowel diseases and multiple sclerosis affecting
71 respectively 0.5% and 0.1% of the population in the Western world.⁸⁻¹² Studies from across the
72 world have reported prevalence estimates of rheumatoid arthritis and psoriasis ranging from
73 0.3%–1.0% and 0.7%–3.2% respectively,^{2 8 13-15} while the prevalence of psoriatic arthritis is estimated
74 as 0.04-0.25% across countries.^{14 16}

75 The CIDs have some shared genetic¹⁷⁻²¹ and environmental (e.g. smoking, gut microbiome)
76 predisposing factors, and causes of the high incidence and prevalence point to such environmental
77 factors.^{8 22-37} Therefore, further research of the associations between potential modifiable
78 environmental risk factors and risk of CID is important.

80 Evidence-based research

81 A study of inflammatory polyarthritis (including RA) has demonstrated that a high level of
82 red meat consumption is a risk factor for the development of inflammatory polyarthritis.^{36 37} A high
83 fibre intake has been associated with low risk of IBD.²⁴ Furthermore, several studies of the impact
84 of dietary factors on multiple sclerosis point towards an impact of meat preservation such as

1
2
3
4 85 smoking or addition of nitrites.³⁸⁻⁴¹ Studies have also suggested other lifestyle factors such as
5
6 86 physical activity,⁴²⁻⁴⁴ BMI,^{1 44-46} smoking status,⁴⁷⁻⁵³ and other dietary factors such as alcohol,^{1 54-56}
7
8 87 dairy products,³⁵ and glycaemic index^{57 58} to be associated with CIDs. Furthermore, studies have
9
10 88 shown that the interactions among the microbiota, female sexual hormones, and immunity are
11
12
13 89 associated with the development of autoimmune diseases.⁵⁹
14
15

16 90 There are many potential mechanisms whereby environment such as diet may affect the
17
18 91 immune system (Figure 1). Recently, we provided the hypothesis that intake of high fibre/low red
19
20 92 and processed meat may protect against CID.⁵⁸ Figure 1 presents a model, proposed in a previous
21
22 93 study,⁸ whereby a diet high in meat and low in fibres may impact inflammation.
23
24
25

94 **FIGURE 1**

95 **Aims and hypotheses**

96 Based on previous evidence, we set out to prospectively identify dietary factors that have an
97 impact on disease risk of CID.
98

99 The primary aim of this prospective cohort study is to investigate the impact of fibre and red
100 and processed meat on disease risk outcomes of CID in the DCH cohort. The overall perspectives
101 are that results from this study will be contributing in supporting future diet recommendations for
102 effective personalized prevention of individuals identified to be at high risk.

103 The main hypothesis is that “the risk of CID will be significantly lower among those with a
104 high fibre/low red and processed meat intake compared to those with a low fibre/high red and
processed meat intake.” The hypothesis is illustrated in figure 1.

1
2
3
4 105 Based on previous research on a shared etiology in CIDs we hypothesize that “the suggested
5
6 106 association between high fibre/low red and processed meat intake and risk of developing CID is
7
8 107 applicable for each of the CID-diagnoses.”

10
11 108 The secondary aim of this prospective cohort study is to investigate whether risk of CID in
12
13 109 the DCH cohort is affected by other dietary and lifestyle differences, and therefore to adjust for the
14
15 110 potential confounders: age, sex, BMI, physical activity, alcohol intake, intake of fermented dairy
16
17 111 products, education after basic school, hormone replacement therapy (HRT), smoking status, and
18
19 112 comorbidity.

20
21
22 113

23 24 114 **METHODS AND ANALYSES**

25 26 115 **Design and setting**

27
28
29
30 116 This study is an observational study using prospective registry follow up data. We will use the
31
32 117 Danish cohort “Diet, Cancer and Health” (DCH), and the follow-up period will be from the date of
33
34 118 entry to the DCH cohort (between December 1993 and May 1997) until May 2018.

35
36
37
38 119 The DCH Study is an ongoing Danish cohort study designed to investigate the relation
39
40 120 between diet, lifestyle, and disease risk.⁶⁰ The cohort consists of 57,053 persons, recruited between
41
42 121 December 1993 and May 1997. All the subjects (50 to 64 years of age) gave detailed information on
43
44 122 diet (food frequency questionnaire) and other lifestyle data. Questionnaire data on diet and
45
46 123 lifestyle were collected at study entry.⁶⁰ Data from the DCH cohort will be combined with Danish
47
48 124 Health registries (the National Patient Registry (NPR), the Danish Civil Registration System (CRS),
49
50 125 The Danish National Prescription Registry (DNPR) and the Danish Multiple Sclerosis Registry
51
52 126 (DMSR).

127 **Participant characteristics and eligibility criteria**

128 *Criteria for inclusion:* The population to be studied include participants in the DCH cohort.⁶⁰

129 In short, the criteria for invitation to the DCH cohort were: age between 50 and 64, born in
130 Denmark, and no diagnosis of cancer registered in the Danish Cancer Registry. All persons
131 fulfilling these criteria and living in the areas of Copenhagen and Aarhus were invited.⁶⁰

132 *Criteria for exclusion:* Participants registered in NPR with a CID primary diagnosis from a
133 department with relevant area of specialization in the period between 1977 and entry to the DCH
134 cohort will be excluded regardless of whether the person receive medical treatment for CID or not.

135 **The Danish health Registries**

136 We will extract data from the four national registries in those time periods that is possible for each
137 registry; NPR from 1977-2018, CRS from 1977-2018, DNPR from 1994-2018, and DMSR from 1977-
138 2018. An overview of the information obtained from the different registries is presented in **table 1**.

Table 1. Overview of registry information

Variable	Definition	Registry	Time period
CPR	Civil Registration Number	CRS**	1977-2018
ICD-10 code*	International Classification of Diseases	NPR**	1994-2018
ICD-8 code*	International Classification of Diseases	NPR	1977-1993
Medication (ATC code)	Anatomical Therapeutic Chemical classification (ATC) code	DNPR**	1994-2018
Treatment code	Medical treatment classification code	NPR	1994-2018
Department with relevant area of specialization	Neurological department of MS, medical department of IBD, department of rheumatology, department of dermatology)	NPR	1977-2018
ICD-8 and ICD-10 codes for MS	Diagnostic codes for multiple sclerosis	DMSR**	1977-2018

*ICD-8 and ICD-10 codes in the period 1977-1993 will be used to exclude participants with a CID diagnosis before entry to the DCH study

**The Danish Civil Registration System (CRS); National Patient Registry (NPR); Danish National Prescription Registry (DNPR); Danish Multiple Sclerosis Registry (DMSR).

1
2
3
4 142 The NPR will be used to identify patients with CID during follow-up and, in addition,
5
6 143 patients with CID before study entry. The NPR contains data on all patients admitted to Danish
7
8 144 hospitals since 1977. The register covers both inpatient and outpatient records and indicates the
9
10 145 main medical reason for diagnostic procedures or treatment (since 1971 according to the eight
11
12 146 version and 1994 according to the tenth version of the International Classification of Diseases (ICD-
13
14 147 8 and ICD-10)). ICD-8 codes will be used to identify cases diagnosed before entry to the DCH
15
16 148 cohort study. Information on the departments with the relevant areas of specialization will be
17
18 149 obtained from the NPR and used to identify cases as described in the data analysis section.
19
20
21
22

23 150 The DMSR will be used to identify patients with multiple sclerosis during follow-up, and in
24
25 151 addition, patients with multiple sclerosis before study entry.
26
27
28

29 152 The DNPR will be used to obtain information on the medical treatment according to the
30
31 153 Anatomical Therapeutic Chemical classification (ATC) code, as it is expected that the patients have
32
33 154 medication in relation to the diseases.
34
35
36

37 155 From the CRS we will extract follow-up information on civil status, death and immigration.
38
39

40 156 **Outcome and exposures**

41
42

43 157 *Outcome:* In this study, the outcome CID is one of the following diseases; the inflammatory
44
45 158 bowel diseases Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, rheumatoid
46
47 159 arthritis, axial spondyloarthritis, or multiple sclerosis. This outcome is defined by fulfilling the
48
49 160 following two criteria: 1) having the CID disease in NPR (except multiple sclerosis) from a
50
51 161 department with relevant area of specialization, or in the DMSR (multiple sclerosis) during the
52
53 162 follow-up period AND 2) being treated (irrespective of the number of treatments) with a drug
54
55
56
57
58
59
60

163 used for the specific disease, and the treatment being registered either in the DNPR or from a
 164 department with relevant area of specialization (criterion 2 will not apply to multiple sclerosis).
 165 The outcome CIDs with the associated ICD-8 and ICD-10 codes and the ATC codes in DNPR and
 166 treatment codes in the NPR are specified in **table 2**. The date and year of the diagnosis is defined
 167 as the date and year of the diagnosis in NPR and/or DMSR.

168 **Table 2. Specification of outcome CIDs with associated diagnostic- and treatment codes**

CID	Diagnostic code (NPR)		Medical treatment (DNPR and NPR)	
	ICD-8*	ICD-10	ATC code (DNPR)***	Treatment code (NPR)***
Crohn's disease	563.01, 563.02	K50.0-50.9	L04AA12	
Ulcerative colitis	563.09, 563.19	K51.0-51.9	L04AB02 L04AA17 L04AB04 L04AB06 L04AB05 L04AA23 L04AA33 A07E	BOHJ18A1 BOHJ18A3 BOHJ18A4 BOHJ18A5 BOHJ26 BOHJ19H4
Rheumatoid arthritis	712.19, 712.29, 712.39, 712.59	M05.9, M06.0, M06.9		
Axial spondyloarthritis	712.49	M45.9, M46.1, M46.8+M02.9, M46.8+M07.4, M46.8+M07.5, M46.9	L04AX01 L04AX03 L04AA13 P01BA02	BWHA115 BLHM2 BWHB83 BOHJ18
Psoriatic arthritis	696.09	M09.0, M07.3, M46.8+M07.2		
Psoriasis	696.10, 696.19	L40.0-40.9	D05AX02 D05BB02 D05B L04AA32 L04AB01-02 L04AB04 L04AC05 L04AC10 L04AC13 L04AD01 L04AX03	BNHC0 BOHJ18A1-3 BOHJ18B3 BOHJ18B5
Multiple sclerosis	734.0-9**	G35.9**	Not used	Not used

*ICD-8 codes will be used to exclude participants with a CID diagnosis code before entry to the DCH study.

**ICD-8 and ICD-10 codes for multiple sclerosis will be extracted from the Danish Multiple Sclerosis Registry

***These ATC and treatment codes for CD and UC are used by the Danish National Registry for Biological Therapy in Inflammatory Bowel Disease (BIO-IBD)⁶¹

1
2
3
4 173 *Exposure and possible confounders:* Information on exposure in this study is defined as high
5
6 174 fibre intake and high red and processed meat intake, and also other dietary and lifestyle factors.

7
8
9 175 In the DCH study, information on diet and lifestyle exposure were collected at enrolment
10
11 176 using questionnaires as has been described in details elsewhere.⁶⁰ In short, the food-frequency
12
13 177 questionnaire (FFQ), diet consumption was assessed in 12 categories of predefined responses,
14
15 178 ranking from “never” to “eight times or more per day over the past 12 months”. The daily intake
16
17 179 was then calculated by FoodCalc.⁶⁰ Both intake of dietary fibre and red meat and processed meat
18
19 180 were measured as continues variable in g/day. The initially collected data on diet and lifestyle
20
21 181 exposure of the DCH cohort is used as the baseline information on exposure in this study.

22
23
24
25
26 182 Information on dietary and lifestyle exposures used for this study is specified in **table 3**.
27
28 183 Fibres, red and processed meat are defined based on the classification of the food items in the DCH
29
30 184 study,⁶⁰ and with inspiration from other studies using dietary data from the DCH cohort.⁶²⁻⁶⁴ Red
31
32 185 meat is defined as fresh and minced meat (unprocessed) from beef, veal, pork, and lamb and
33
34 186 excluding poultry, fish, or eggs. Red processed meat consists of red meat items that have
35
36 187 undergone processing such as smoking, salting or curing. This includes various kinds of sausages,
37
38 188 salami, smoked or cooked ham, other cold cuts, bacon and liver pate. Poultry includes chicken and
39
40 189 turkey both unprocessed and processed, such as various cold cuts of chicken and turkey. Fish
41
42 190 includes all unprocessed and processed fish as well as shellfish. Total meat is defined as the total of
43
44 191 red (unprocessed) meat, red processed meat together with poultry and fish.⁶²⁻⁶⁴ Fibres are defined
45
46 192 as fibres from fibrous food items from the FFQ.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 193 Information on possible confounders will also be obtained from the questionnaire data at
5
6 194 enrolment in relation to sex, age, education after basic school, BMI, physical activity, HRT,
7
8 195 comorbidity, smoking status, alcohol intake, and also intake of fermented dairy products. The
9
10
11 196 Charlsons comorbidity index⁶⁵ will be used to classify comorbidity among the study participants.
12
13 197 ICD-8 and ICD-10 codes from the NPR will be used to calculate the Charlson score, using the
14
15 198 updated Charlson comorbidity index.⁶⁶
16
17

18 **Table 3. Specification of exposures and overall food groups and lifestyle factors**

Variable	Definition (unit)
<i>Diet</i>	
Total energy intake	kJ/day
Total meat	g/day
Red meat	g/day
Red processed meat	g/day
Fish (fresh and processed)	g/day
Poultry (fresh and processed)	g/day
Total dietary fiber intake	g/day
Legumes	g/day
Vegetables	g/day
Fruits	g/day
Cereals	g/day
Dairy products	g/day
<i>Lifestyle factors</i>	
Alcohol intake	units of alcohol/week*
Smoking status	yes/no
Former smoker	
Current smoker	
Never smoker	
MET-score (physical activity)	hours/week
BMI	kg/cm ²
Highest education after basic school	yes/no
Vocational education	
Higher education 1-2 years	

Higher education 3-4 years

Higher education > 4 years

Co-morbidity (Charlson comorbidity index) index score

Hormone replacement therapy (HRT) yes/no

199 *One unit of alcohol is defined as 12 grams of pure alcohol

200 *Primary exposure variable:* The primary exposure variables will be analyzed in tertiles. Based on the
 201 hypothesis that the risk of CID will be lower among those with a high fibre/low red and processed
 202 meat intake compared to those with a low fibre/high red and processed meat intake, it is expected
 203 that:

- 204 • The upper tertile of the sample (33.3% of the total sample), based on the ratio of fibre/meat
 205 intake, is associated with lower risk of CID.
- 206 • The lower tertile of the sample (33.3% of the total sample) with respect to intake of red meat
 207 and processed meat and the upper tertile of the sample (33.3% of the total sample) with
 208 respect to intake of dietary fibres are independently associated with lower risk of CID, and
 209 a potential interaction between them may further lower the risk of CID.

210 *Other (exploratory) exposure variables:*

- 211 • Other dietary and lifestyle factors independently or combined will be analysed, and are
 212 presented in table 3.

213 **Statistical analysis plan**

214 The data obtained from this study will be used to investigate our ability to predict risk of
 215 CID, based on whether a diet high in fibre and low in red and processed meat is a predictive
 216 factor. Furthermore, data on other lifestyle factors and dietary factors obtained from the FFQ will

1
2
3
4 217 be used to investigate whether these factors potentially could give risen to confounding of the
5
6 218 association between fibre/meat intake and risk of CID.
7

8 219 Descriptive analyses for categorical variables will be presented as frequencies, and
9
10 220 differences between CID cases and non-cases will be evaluated by Chi-square test. Continuous
11
12 221 variables will be tabulated as medians (with quartiles, Q1 and Q3) and nonparametric tests on the
13
14 222 equality of medians will be used to test for differences between groups. P-values below 0.05 will be
15
16 223 considered statistically significant. Negative binomial regression will be applied to calculate
17
18 224 incidence rates per 1,000 patient years and incidence rate ratios (IRR) between exposures. To
19
20 225 investigate the risk of and time to CID-diagnosis the Fine-Gray competing risk regression model
21
22 226 will be applied, and thus competing risk of death will be taken into account while handling
23
24 227 emigration as censoring and reporting cumulative incidences and sub-hazard ratios (SHR) and the
25
26 228 corresponding p-values for CID associated with specified food substitutions. Regressions will be
27
28 229 carried out as both crude regression, only including the exposure, and adjusted for age, sex,
29
30 230 lifestyle factors and selected comorbidities. Analyses will be conducted using Stata version 15.⁶⁷
31
32
33
34
35

36 231 If power of each of the disease groups allows, there will be conducted sub-analyses on each
37
38 232 of the CID diagnoses separately with the overall aim of testing if the hypothesized association
39
40 233 between diet factors and development of CID is applicable for all the CIDs or if some of the CIDs
41
42 234 deviate from this association.
43
44

45 235 Information on the departments with the relevant areas of specialization will be used to
46
47 236 evaluate the robustnes of the diagnosis codes from the NPR and to identify the cases as we will
48
49 237 only accept cases that have a diagnosis from a relevant department (e.g. department for
50
51 238 rheumatology, medical department for inflammatory bowel disease). The Danish Multiple Sclerosis
52
53
54
55
56
57
58
59
60

239 registry is highly validated,⁶⁸ and data from the registry will be used to ensure complete follow-up
240 of valid diagnoses of multiple sclerosis.

241 *Power considerations:* The age-adjusted (age between 45-69) incidences per 100,000 years of the
242 CIDs in Denmark are 10.1-10.6 for Crohn's disease⁶⁹; 27.5-32.7 for ulcerative colitis⁶⁹; 200-225 for
243 psoriasis¹⁵; 28-35 for psoriatic arthritis¹⁶; 4.4-7.5 for multiple sclerosis⁷⁰⁻⁷⁴; and 28.1-57.6 for
244 rheumatoid arthritis⁷⁵⁻⁷⁶. The incidence of axSpA is low in this age group in Denmark,⁷⁷⁻⁷⁸ hence the
245 incidence of axSpA in the study population of this study will be considerably low. In the cohort of
246 approximately 57,000 participants and a follow-up period of approximately 20 years, these
247 incidences correspond to an estimate of approximately 2,000 cases of CID in the cohort. To
248 estimate the power of the study we therefore expect approximately 2,000 cases of CID, i.e. an
249 incidence of about 3% and about one third of the cohort in the low risk and two thirds in the high
250 risk exposure. Assuming a fixed follow-up of 20 years and a relevant effect size of 2% CID risk in
251 the low risk exposure compared to 3% in the high risk exposure this would require 11,667
252 participants to obtain a power of 0.90 in an (unadjusted) Chi-squared-test. Hence with a total
253 cohort size of approximately 57,000, this should ensure a sufficient power even when taking loss to
254 emigration and competing risk of death (resulting in less than 20 years follow-up for some
255 participants) into account.

256 **Strengths and limitations of the study**

257 A strength of this study is that it is not limited to one disease, as it includes several chronic
258 inflammatory diseases. Another strength is that the linkage to Danish Health registries will ensure
259 almost complete follow-up of the study population, as the Danish Health registries are considered
260 the internationally most comprehensive with high validity.⁷⁹⁻⁸² Furthermore, in this study, we have
261 chosen very restrictive criteria for defining the CID cases by requiring that CID cases fulfill both

1
2
3
4 262 diagnostic and treatment criteria, or that the cases were registered in the DMSR. This approach
5
6 263 ensures that a high proportion of the identified cases really had CID. Therefore, some “real” CID
7
8 264 cases might not have been identified, hence lowering the sensitivity.^{68 83 84}

10
11 265 A possible limitation of this study could have been the validity of the diagnostic codes from
12
13 266 the NPR and the treatment codes from the DNPR as criteria for identifying CID cases.^{68 83} But, as
14
15 267 described in the analysis plan this potential limitation will be sought eliminated by using the
16
17 268 information on the hospital departments, and for MS, using the DMSR for identifying MS cases.

19
20 269 The FFQ applied in the present study has been used in the large, European prospective
21
22 270 cohort study “The European Prospective Investigation into Cancer and Nutrition” (EPIC),^{85 86} and
23
24 271 it has been used and evaluated in the Danish population, with results that demonstrate
25
26 272 consistency.⁸⁷⁻⁸⁹ However, the FFQ is not without limitations, with respect to the lack of
27
28 273 information on portion sizes^{90 91} or to underestimation and overestimation of intake of unhealthy
29
30 274 and healthy food.⁹² Any imprecision of the FFQ due to standardized portion sizes or incorrect
31
32 275 reporting of food intake, will lead to large confidence intervals, which potentially can lead to null
33
34 276 results.⁸ On the other hand, studies suggest that specification of a standard portion size may not
35
36 277 introduce a large error in the estimation of food and nutrient intake.⁹³ Furthermore, the FFQ has
37
38 278 been validated as being appropriate for use in studies that examine relationships between diet and
39
40 279 risk of disease.⁹²

41
42 280 Another limitation of this study is the validity of the information on exposure as this
43
44 281 information is collected at study entry, which potentially can be several years before any outcome
45
46 282 appears, and measurement error in the FFQ may occur if the participants change their diet over
47
48 283 time. Furthermore, there is a potential risk of recall bias according to the information on exposure,
49
50 284 as this information relies on the participants ability to recall their dietary intake. In this study,
51
52
53
54
55
56
57
58
59
60

1
2
3
4 285 however, it is expected that dietary and lifestyle patterns among adults are relatively stable over
5
6 286 time, based on other longitudinal studies that showed minimal temporal changes.^{94 95}
7

8 287 The MET-score is an accepted standard measure of physical activity.⁹⁶ However, the
9
10 288 weaknesses of the MET-score include a risk of adding random variation by applying an assumed
11
12 289 intensity to include activities. Another weakness of the MET-score is the implicit assumption that
13
14 290 the intensity aspect of physical activity is important for development of disease.⁹⁶
15
16

17
18 291 The study population in this study is based on a cohort of middle-aged women and men
19
20 292 living in urban areas. This could reduce the generalizability of study findings, as the proportion of
21
22 293 CID diagnoses could be different for younger or elder persons or persons from rural areas.
23

24
25 294 The disease groups may be heterogeneous regarding dietary and lifestyle factors. This study
26
27 295 may not capture every dietary and lifestyle difference between the disease groups, due to
28
29 296 insufficient power of each disease group, as described in the analysis plan. Replication of the
30
31 297 results in other well-characterized populations using prospectively sampled dietary data will
32
33 298 minimize the risk of potential type 2 errors. Study results should preferably be replicated in
34
35 299 cohorts in other countries and other age groups for further evaluation of the robustness of the
36
37 300 results.
38
39
40
41

42 301 **Project organisation**

43
44
45 302 This registry study is a cross-disciplinary collaboration that includes clinical specialists within
46
47 303 neurology, dermatology, rheumatology, inflammatory bowel diseases, prospective cohort study
48
49 304 design, and clinical registries.
50

51 52 53 305 **Perspectives** 54 55 56 57 58 59 60

1
2
3
4 306 We anticipate that the PROCID-DCH study will reveal factors of importance, including whether
5
6 307 the diet is likely to interfere with the disease risk of CID.
7
8

9 308 The perspective is that significant results from this study will be sought replicated in other
10
11 309 cohorts such as the EPIC-IBD⁸⁵ and UK biobank⁹⁷ with high-quality prospective lifestyle data.
12
13 310 Successful replication indicates the robustness of the findings which is an important step on the
14
15 311 road to developing clinical tools for effective personalized prevention of individuals at high risk.
16
17
18

19 312 **Dissemination of results to the public and scientifically**

20
21
22 313 Target journals include international journals within internal medicine. In addition to the scientific
23
24 314 reporting of results, major findings with translational implications will also be communicated to
25
26 315 categories of both health professionals, and targeted stakeholders including public health
27
28 316 policymakers, and to the general public through various media and news activities. Intellectual
29
30 317 Property Rights (IPRs) to discoveries based upon the outlined research belong to the University of
31
32 318 Southern Denmark.
33
34
35

36 37 319 **Ethics**

38
39
40 320 This is an open register-based cohort study. The study does not need approval from the local
41
42 321 Ethics committee or Institutional Review Board by Danish law. The study was approved by the
43
44 322 Danish Data Protection Agency (2012-58-0018).
45
46
47

48 323 **Funding**

49
50 324 This work is supported by Region of Southern Denmark grant number [17/33849] (Vibeke
51
52 325 Andersen).
53

54 326 **Author Contributions:**

1
2
3
4 327 NFR, KHR and VA wrote the first draft and contributed to the further preparation and final
5
6 328 adjustments of the protocol. All authors critically read and accepted the final submitted version.
7

8
9 329 **Conflicts of Interest:**

10
11 330 BG declares to have received research funding from Abbvie, Biogen, Pfizer. MLH declares to have
12
13 331 received research funding from BMS, MSD, Pfizer, Biogen, Samsung, CellTrion, Lilly, Novartis. All
14
15
16 332 other authors declare no conflict of interest.
17

18 333
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGEND**Figure 1. Hypothesis for effects of diet in relation to development of chronic inflammatory diseases (CID)**

Diet (meat⁹⁸, fibre⁹⁸, animal fat⁹⁹, n-3²⁷ and n-6 polyunsaturated fatty acids, vitamin A¹⁰⁰ and D¹⁰¹, carotenoids¹⁰², smoking, gluten¹⁰³) may affect the immune system^{104 105} either directly or indirectly via e.g. the activity and composition of the gut microbiome.^{106 107} The effect of low intake of fiber/high intake of red and processed meat is shown at left: In short, low intake of fibre (which could otherwise serve as a nutrient for the microbes) may lead to the microbial metabolism of mucus and to decrease of the intestinal mucus layer.⁵⁸ A high intake of red and processed meat (containing organic sulphur and sulphate additives) may render the mucus layer penetrable to e.g. bacteria by reducing the disulphide bonds in the mucus network.⁸ Thus, microbes may reach the epithelium^{8 111 112} and activate the immune system.^{8 113 114} There is some support for such a mechanism in CID⁸, including findings of; high amounts of sulphate-reducing bacteria in IBD patients;^{8 112 115} association of high fibre intake with low risk of IBD among 170 776 participants from the prospective Nurses' Health Study I (NHSI)^{8 24}; and association of high intake of red meat and total protein and risk of developing inflammatory polyarthritis in the population-based prospective cohort of 25 630 participants from the European Prospective Investigation of Cancer in Norfolk (EPIC-Norfolk).^{8 36 37}

Note. Figure from "Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine," by Christensen R, Heitmann BL, Andersen KW, et al., *BMJ Open* 2018;8:e018166. doi: 10.1136/bmjopen-2017-018166. Available at: <http://bmjopen.bmj.com/content/8/2/e018166>. Copyright 2018 by Vibeke Andersen.

Reference list

1. Amato M, Derfuss, T, Hemmer, B, Liblau, R, Montalban, X, Soelberg, PS, Miller, DH. Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. *Multiple Sclerosis Journal* 2017;1-14. doi: doi.org/10.1177/1352458516686847
2. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *The Journal of investigative dermatology* 2013;133(2):377-85. doi: 10.1038/jid.2012.339 [published Online First: 2012/09/28]
3. Baumgart DC, Carding SR. Gastroenterology 1: Inflammatory bowel disease: cause and immunobiology. *The Lancet* 2007;369(9573):1627.
4. Baumgart DC, Sandborn WJ. Gastroenterology 2: Inflammatory bowel disease: clinical aspects and established and evolving therapies. *The Lancet* 2007;369(9573):1641.
5. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. *The Journal of clinical investigation* 2007;117(3):514-21. doi: 10.1172/JCI30587
6. Taurog JD, Chhabra A, Colbert RA. Ankylosing Spondylitis and Axial Spondyloarthritis. *The New England journal of medicine* 2016;374(26):2563-74. doi: 10.1056/NEJMra1406182
7. Löfvendahl S, Theander E, Svensson Å, et al. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. *PLoS one* 2014;9(5):e98024. doi: 10.1371/journal.pone.0098024
8. Christensen R, Heitmann BL, Andersen KW, et al. Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine. *BMJ open* 2018;8(2):e018166. doi: 10.1136/bmjopen-2017-018166 [published Online First: 2018/02/14]
9. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012;142(1):46-54.e42; quiz e30. doi: 10.1053/j.gastro.2011.10.001 [published Online First: 2011/10/18]
10. Leray E, Moreau T, Fromont A, et al. Epidemiology of multiple sclerosis. *Revue neurologique* 2016;172(1):3-13. doi: 10.1016/j.neurol.2015.10.006
11. Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. *Neurology* 2014;83(11):1022-4. doi: 10.1212/wnl.0000000000000768 [published Online First: 2014/09/10]
12. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *The Lancet* 2017;390(10114):2769-78. doi: 10.1016/S0140-6736(17)32448-0
13. WHO. Chronic Diseases and Health Promotion 2017 [Available from: <http://www.who.int/chp/topics/rheumatic/en/>].
14. Poddubnyy D, Rudwaleit M. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. *Expert opinion on drug safety* 2011;10(4):655-73. doi: 10.1517/14740338.2011.581661 [published Online First: 2011/05/11]
15. Egeberg A, Skov L, Gislason GH, et al. Incidence and Prevalence of Psoriasis in Denmark. *Acta dermatovenereologica* 2017;97(7):808-12. doi: 10.2340/00015555-2672 [published Online First: 2017/04/19]
16. Egeberg A, Kristensen LE, Thyssen JP, et al. Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. *Annals of the rheumatic diseases* 2017;76(9):1591-97. doi: 10.1136/annrheumdis-2016-210963 [published Online First: 2017/05/10]
17. Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nature genetics* 2013;45(11):1353-60. doi: 10.1038/ng.2770 [published Online First: 2013/10/01]

- 1
2
3
4 401 18. Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new
5 402 associations and highlights disease-specific patterns at shared loci. *Nature genetics* 2016;48(5):510-8.
6 403 doi: 10.1038/ng.3528 [published Online First: 2016/03/15]
7 404 19. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci,
8 405 increasing the number of confirmed associations to 47. *Nature genetics* 2011;43(3):246-52. doi:
9 406 10.1038/ng.764 [published Online First: 2011/02/08]
10 407 20. Ellinghaus D, Zhang H, Zeissig S, et al. Association between variants of PRDM1 and NDP52 and Crohn's
11 408 disease, based on exome sequencing and functional studies. *Gastroenterology* 2013;145(2):339-47. doi:
12 409 10.1053/j.gastro.2013.04.040 [published Online First: 2013/04/30]
13 410 21. Goyette P, Boucher G, Mallon D, et al. High-density mapping of the MHC identifies a shared role for
14 411 HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis.
15 412 *Nature genetics* 2015;47(2):172-9. doi: 10.1038/ng.3176 [published Online First: 2015/01/07]
16 413 22. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with
17 414 reduced risk of Crohn's disease. *Gastroenterology* 2012;142(3):482-9. doi: 10.1053/j.gastro.2011.11.040
18 415 [published Online First: 2011/12/14]
19 416 23. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative
20 417 colitis and Crohn's disease. *Gut* 2014;63(5):776-84. doi: 10.1136/gutjnl-2013-305304 [published Online
21 418 First: 2013/07/06]
22 419 24. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A Prospective Study of Long-term Intake of Dietary
23 420 Fiber and Risk of Crohn's Disease and Ulcerative Colitis. *Gastroenterology* 2013;145(5):970-77. doi:
24 421 10.1053/j.gastro.2013.07.050
25 422 25. Ananthakrishnan AN, Khalili H, Song M, et al. Zinc intake and risk of Crohn's disease and ulcerative
26 423 colitis: a prospective cohort study. *International journal of epidemiology* 2015;44(6):1995-2005. doi:
27 424 10.1093/ije/dyv301 [published Online First: 2015/11/08]
28 425 26. Ananthakrishnan AN, Khalili H, Song M, et al. High School Diet and Risk of Crohn's Disease and
29 426 Ulcerative Colitis. *Inflammatory bowel diseases* 2015;21(10):2311-9. doi: 10.1097/mib.0000000000000501
30 427 [published Online First: 2015/08/04]
31 428 27. Chan SS, Luben R, Olsen A, et al. Association between high dietary intake of the n-3 polyunsaturated
32 429 fatty acid docosahexaenoic acid and reduced risk of Crohn's disease. *Alimentary pharmacology &
33 430 therapeutics* 2014;39(8):834-42. doi: 10.1111/apt.12670 [published Online First: 2014/03/13]
34 431 28. Chan SSM, Luben R, Olsen A, et al. Body mass index and the risk for Crohn's disease and ulcerative
35 432 colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). *The American
36 433 journal of gastroenterology* 2013;108(4):575. doi: 10.1038/ajg.2012.453
37 434 29. Chan SS, Luben R, van Schaik F, et al. Carbohydrate intake in the etiology of Crohn's disease and
38 435 ulcerative colitis. *Inflammatory bowel diseases* 2014;20(11):2013-21. doi: 10.1097/mib.0000000000000168
39 436 [published Online First: 2014/09/30]
40 437 30. John S, Luben R, Shrestha SS, et al. Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative
41 438 colitis: a UK prospective cohort study. *European journal of gastroenterology & hepatology* 2010;22(5):602-
42 439 6. doi: 10.1097/MEG.0b013e3283352d05 [published Online First: 2010/03/11]
43 440 31. de Silva PS, Luben R, Shrestha SS, et al. Dietary arachidonic and oleic acid intake in ulcerative colitis
44 441 etiology: a prospective cohort study using 7-day food diaries. *European journal of gastroenterology &
45 442 hepatology* 2014;26(1):11-8. doi: 10.1097/MEG.0b013e328365c372 [published Online First: 2013/11/13]
46 443 32. de Silva PS, Olsen A, Christensen J, et al. An association between dietary arachidonic acid, measured in
47 444 adipose tissue, and ulcerative colitis. *Gastroenterology* 2010;139(6):1912-7. doi:
48 445 10.1053/j.gastro.2010.07.065 [published Online First: 2010/10/19]
49 446 33. Hart AR, Luben R, Olsen A, et al. Diet in the aetiology of ulcerative colitis: a European prospective cohort
50 447 study. *Digestion* 2008;77(1):57-64. doi: 10.1159/000121412 [published Online First: 2008/03/20]
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 448 34. Opstelten JL, Leenders M, Dik VK, et al. Dairy Products, Dietary Calcium, and Risk of Inflammatory
5 449 Bowel Disease: Results From a European Prospective Cohort Investigation. *Inflammatory bowel*
6 450 *diseases* 2016;22(6):1403-11. doi: 10.1097/mib.0000000000000798 [published Online First: 2016/04/28]
7 451 35. Bordoni A, Danesi F, Dardevet D, et al. Dairy products and inflammation: A review of the clinical
8 452 evidence. *Critical reviews in food science and nutrition* 2017;57(12):2497-525. doi:
9 453 10.1080/10408398.2014.967385 [published Online First: 2015/08/20]
10 454 36. Lahiri M, Luben RN, Morgan C, et al. Using lifestyle factors to identify individuals at higher risk of
11 455 inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk
12 456 and the Norfolk Arthritis Register--the EPIC-2-NOAR Study). *Annals of the rheumatic diseases*
13 457 2014;73(1):219-26. doi: 10.1136/annrheumdis-2012-202481 [published Online First: 2013/03/19]
14 458 37. Pattison DJ, Symmons DP, Lunt M, et al. Dietary risk factors for the development of inflammatory
15 459 polyarthritis: evidence for a role of high level of red meat consumption. *Arthritis and rheumatism*
16 460 2004;50(12):3804-12. doi: 10.1002/art.20731 [published Online First: 2004/12/14]
17 461 38. Lauer K. Multiple sclerosis in relation to meat preservation in France and Switzerland. *Neuroepidemiology*
18 462 1989;8(6):308-15. doi: 10.1159/000110199 [published Online First: 1989/01/01]
19 463 39. Lauer K. The food pattern in geographical relation to the risk of multiple sclerosis in the Mediterranean
20 464 and Near East region. *Journal of epidemiology and community health* 1991;45(3):251-2. [published Online
21 465 First: 1991/09/01]
22 466 40. Lauer K. Notes on the epidemiology of multiple sclerosis, with special reference to dietary habits.
23 467 *International journal of molecular sciences* 2014;15(3):3533-45. doi: 10.3390/ijms15033533 [published
24 468 Online First: 2014/03/01]
25 469 41. Lauer K. The history of nitrite in human nutrition: a contribution from German cookery books. *Journal of*
26 470 *clinical epidemiology* 1991;44(3):261-4. [published Online First: 1991/01/01]
27 471 42. Sharif K, Watad A, Bragazzi NL, et al. Physical activity and autoimmune diseases: Get moving and
28 472 manage the disease. *Autoimmunity reviews* 2018;17(1):53-72. doi: 10.1016/j.autrev.2017.11.010
29 473 [published Online First: 2017/11/08]
30 474 43. Jones PD, Kappelman MD, Martin CF, et al. Exercise decreases risk of future active disease in patients
31 475 with inflammatory bowel disease in remission. *Inflammatory bowel diseases* 2015;21(5):1063-71. doi:
32 476 10.1097/mib.0000000000000333 [published Online First: 2015/02/28]
33 477 44. Bilski J, Mazur-Bialy AI, Wierdak M, et al. The impact of physical activity and nutrition on inflammatory
34 478 bowel disease: the potential role of cross talk between adipose tissue and skeletal muscle. *Journal of*
35 479 *physiology and pharmacology : an official journal of the Polish Physiological Society* 2013;64(2):143-55.
36 480 [published Online First: 2013/06/13]
37 481 45. Wolk K, Mallbris L, Larsson P, et al. Excessive body weight and smoking associates with a high risk of
38 482 onset of plaque psoriasis. *Acta dermato-venereologica* 2009;89(5):492-7. doi: 10.2340/00015555-0711
39 483 [published Online First: 2009/09/08]
40 484 46. Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. *Scandinavian journal of*
41 485 *rheumatology* 2006;35(3):169-74. doi: 10.1080/03009740600718080 [published Online First: 2006/06/13]
42 486 47. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. *Mayo*
43 487 *Clinic proceedings* 2006;81(11):1462-71. doi: 10.4065/81.11.1462
44 488 48. Klareskog L, Malmstrom V, Lundberg K, et al. Smoking, citrullination and genetic variability in the
45 489 immunopathogenesis of rheumatoid arthritis. *Seminars in immunology* 2011;23(2):92-8. doi:
46 490 10.1016/j.smim.2011.01.014 [published Online First: 2011/03/08]
47 491 49. Li W, Han J, Choi HK, et al. Smoking and risk of incident psoriasis among women and men in the United
48 492 States: a combined analysis. *American journal of epidemiology* 2012;175(5):402-13. doi:
49 493 10.1093/aje/kwr325 [published Online First: 2012/01/17]
50 494 50. Costenbader KH, Feskanich D, Mandl LA, et al. Smoking intensity, duration, and cessation, and the risk
51 495 of rheumatoid arthritis in women. *The American journal of medicine* 2006;119(6):503.e1-9. doi:
52 496 10.1016/j.amjmed.2005.09.053 [published Online First: 2006/06/06]

- 1
2
3
4 497 51. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. *The*
5 498 *American journal of medicine* 2007;120(11):953-9. doi: 10.1016/j.amjmed.2007.06.020 [published Online
6 499 First: 2007/11/03]
7 500 52. Alfredsson L, Olsson T. Lifestyle and Environmental Factors in Multiple Sclerosis. *Cold Spring Harbor*
8 501 *perspectives in medicine* 2018 doi: 10.1101/cshperspect.a028944 [published Online First: 2018/05/08]
9 502 53. Palacios N, Alonso A, Bronnum-Hansen H, et al. Smoking and increased risk of multiple sclerosis:
10 503 parallel trends in the sex ratio reinforce the evidence. *Annals of epidemiology* 2011;21(7):536-42. doi:
11 504 10.1016/j.annepidem.2011.03.001 [published Online First: 2011/05/10]
12 505 54. Swanson GR, Sedghi S, Farhadi A, et al. Pattern of alcohol consumption and its effect on gastrointestinal
13 506 symptoms in inflammatory bowel disease. *Alcohol (Fayetteville, NY)* 2010;44(3):223-8. doi:
14 507 10.1016/j.alcohol.2009.10.019 [published Online First: 2010/08/05]
15 508 55. Khasawneh M, Spence AD, Addley J, et al. The role of smoking and alcohol behaviour in the
16 509 management of inflammatory bowel disease. *Best practice & research Clinical gastroenterology*
17 510 2017;31(5):553-59. doi: 10.1016/j.bpg.2017.10.004 [published Online First: 2017/12/03]
18 511 56. Abdollahpour I, Nedjat S, Mansournia MA, et al. Lifestyle factors and multiple sclerosis: A population-
19 512 based incident case-control study. *Multiple sclerosis and related disorders* 2018;22:128-33. doi:
20 513 10.1016/j.msard.2018.03.022 [published Online First: 2018/04/21]
21 514 57. Kelly KR, Haus JM, Solomon TPJ, et al. A Low-Glycemic Index Diet and Exercise Intervention Reduces
22 515 TNF[alpha] in Isolated Mononuclear Cells of Older, Obese Adults^{1,2}. *The Journal of Nutrition*
23 516 2011;141(6):1089.
24 517 58. Andersen V, Hansen AK, Heitmann BL. Potential Impact of Diet on Treatment Effect from Anti-TNF
25 518 Drugs in Inflammatory Bowel Disease. *Nutrients* 2017;9(3) doi: 10.3390/nu9030286 [published Online
26 519 First: 2017/03/16]
27 520 59. Vieira AT, Castelo PM, Ribeiro DA, et al. Influence of Oral and Gut Microbiota in the Health of
28 521 Menopausal Women. *Frontiers in Microbiology* 2017;8 doi: 10.3389/fmicb.2017.01884
29 522 60. Tjonneland A, Olsen A, Boll K, et al. Study design, exposure variables, and socioeconomic determinants
30 523 of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053
31 524 men and women in Denmark. *Scandinavian journal of public health* 2007;35(4):432-41. doi:
32 525 10.1080/14034940601047986 [published Online First: 2007/09/06]
33 526 61. Larsen L, Jensen M, Larsen MD, et al. The Danish National Registry for Biological Therapy in
34 527 Inflammatory Bowel Disease. *Clinical Epidemiology* 2016;8:607-12. doi: 10.2147/CLEP.S99478
35 528 62. Wurtz AM, Hansen MD, Tjonneland A, et al. Substitution of meat and fish with vegetables or potatoes
36 529 and risk of myocardial infarction. *The British journal of nutrition* 2016;116(9):1602-10. doi:
37 530 10.1017/s0007114516003500 [published Online First: 2016/10/25]
38 531 63. Sorensen M, Autrup H, Olsen A, et al. Prospective study of NAT1 and NAT2 polymorphisms, tobacco
39 532 smoking and meat consumption and risk of colorectal cancer. *Cancer letters* 2008;266(2):186-93. doi:
40 533 10.1016/j.canlet.2008.02.046 [published Online First: 2008/03/29]
41 534 64. Egeberg R, Olsen A, Christensen J, et al. Associations between red meat and risks for colon and rectal
42 535 cancer depend on the type of red meat consumed. *J Nutr* 2013;143(4):464-72. doi:
43 536 10.3945/jn.112.168799 [published Online First: 2013/02/22]
44 537 65. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in
45 538 longitudinal studies: Development and validation. *Journal of Chronic Diseases* 1987;40(5):373-83. doi:
46 539 10.1016/0021-9681(87)90171-8
47 540 66. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for
48 541 risk adjustment in hospital discharge abstracts using data from 6 countries. *American journal of*
49 542 *epidemiology* 2011;173(6):676-82. doi: 10.1093/aje/kwq433
50 543 67. Stata Statistical Software [program]. 15 version, 2017.
51 544 68. Mason K, Thygesen LC, Stenager E, et al. Evaluating the use and limitations of the Danish National
52 545 Patient Register in register-based research using an example of multiple sclerosis. *Acta neurologica*

- 1
2
3
4 546 *Scandinavica* 2012;125(3):213-7. doi: 10.1111/j.1600-0404.2011.01558.x [published Online First:
5 547 2011/06/28]
- 6 548 69. Lophaven SN, Lynge E, Burisch J. The incidence of inflammatory bowel disease in Denmark 1980-2013: a
7 549 nationwide cohort study. *Alimentary pharmacology & therapeutics* 2017;45(7):961-72. doi:
8 550 10.1111/apt.13971 [published Online First: 2017/02/24]
- 9 551 70. Kingwell E, Marriott JJ, Jetté N, et al. Incidence and prevalence of multiple sclerosis in Europe: a
10 552 systematic review. *BMC neurology* 2013;13(1):128. doi: 10.1186/1471-2377-13-128
- 11 553 71. Bentzen J, Meulengracht Flachs E, Stenager E, et al. Prevalence of multiple sclerosis in Denmark 1950–
12 554 2005. *Multiple Sclerosis Journal* 2010;16(5):520-25. doi: 10.1177/1352458510364197
- 13 555 72. Koch-Henriksen N, Thygesen LC, Stenager E, et al. Incidence of MS has increased markedly over six
14 556 decades in Denmark particularly with late onset and in women. *Neurology* 2018;90(22):e1954-e63.
15 557 doi: 10.1212/wnl.0000000000005612 [published Online First: 2018/05/04]
- 16 558 73. Koch-Henriksen N, Magyari M, Laursen B. Registers of multiple sclerosis in Denmark. *Acta neurologica*
17 559 *Scandinavica* 2015;132(199):4-10. doi: 10.1111/ane.12424 [published Online First: 2015/06/06]
- 18 560 74. Society TDMS. Fakta om sclerose 2013 [Available from: <https://scleroseforeningen.dk/viden-og-nyt/hvad-er-sclerose/fa-alle-tallene-om-sclerose>
19 561 accessed May 2018.
- 20 562 75. Kiadaliri AA, Kristensen LE, Englund M. Burden of rheumatoid arthritis in the Nordic region, 1990-2015:
21 563 a comparative analysis using the Global Burden of Disease Study 2015. *Scandinavian journal of*
22 564 *rheumatology* 2018;47(2):1-101. doi: 10.1080/03009742.2017.1314002 [published Online First:
23 565 2017/08/03]
- 24 566 76. Pedersen JK, Svendsen AJ, Horslev-Petersen K. Incidence of Rheumatoid Arthritis in the Southern part of
25 567 Denmark from 1995 to 2001. *The open rheumatology journal* 2007;1:18-23. doi:
26 568 10.2174/1874312900701010018 [published Online First: 2007/01/01]
- 27 569 77. Mathieson HR, Marzo-Ortega H. Axial spondyloarthritis: diagnosis and management : PRESCRIBING IN
28 570 PRACTICE. *Prescriber* 2014;25(23-24):32-36. doi: 10.1002/psb.1290
- 29 571 78. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society
30 572 (ASAS) handbook: a guide to assess spondyloarthritis. *Annals of the rheumatic diseases* 2009;68 Suppl
31 573 2(6):iii. doi: 10.1136/ard.2008.104018
- 32 574 79. Pedersen CB. The Danish Civil Registration System. *Scandinavian journal of public health*
33 575 2011;39(7_suppl):22-25. doi: 10.1177/1403494810387965
- 34 576 80. Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient Registry: a review of content,
35 577 data quality, and research potential. *Clinical epidemiology* 2015;7:449-90. doi: 10.2147/CLEP.S91125
- 36 578 81. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data Resource Profile: The Danish National
37 579 Prescription Registry. *International journal of epidemiology* 2016:dyw213. doi: 10.1093/ije/dyw213
- 38 580 82. Helweg-Larsen K. The Danish Register of Causes of Death. *Scandinavian journal of public health*
39 581 2011;39(7_suppl):26-29. doi: 10.1177/1403494811399958
- 40 582 83. Ibfelt EH, Sorensen J, Jensen DV, et al. Validity and completeness of rheumatoid arthritis diagnoses in the
41 583 nationwide DANBIO clinical register and the Danish National Patient Registry. *Clin Epidemiol*
42 584 2017;9:627-32. doi: 10.2147/lep.S141438 [published Online First: 2017/12/15]
- 43 585 84. Lindhardtsen J, Gislason GH, Jacobsen S, et al. Non-steroidal anti-inflammatory drugs and risk of
44 586 cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. *Annals of the*
45 587 *rheumatic diseases* 2014;73(8):1515-21. doi: 10.1136/annrheumdis-2012-203137 [published Online First:
46 588 2013/06/12]
- 47 589 85. European prospective investigation into cancer and nutrition E. EPIC Study 2014 [Available from:
48 590 <http://epic.iarc.fr/> accessed March 2018.
- 49 591 86. Racine A, Carbonnel F, Chan SS, et al. Dietary Patterns and Risk of Inflammatory Bowel Disease in
50 592 Europe: Results from the EPIC Study. *Inflammatory bowel diseases* 2016;22(2):345-54. doi:
51 593 10.1097/mib.0000000000000638 [published Online First: 2015/12/31]

- 1
2
3
4 594 87. Togo P, Heitmann BL, Sorensen TI, et al. Consistency of food intake factors by different dietary
5 595 assessment methods and population groups. *The British journal of nutrition* 2003;90(3):667-78.
6 596 [published Online First: 2003/09/18]
7 597 88. Tjonneland A, Overvad K, Haraldsdottir J, et al. Validation of a semiquantitative food frequency
8 598 questionnaire developed in Denmark. *IntJ Epidemiol* 1991;20(4):906-12.
9 599 89. Osler M, Heitmann BL. The validity of a short food frequency questionnaire and its ability to measure
10 600 changes in food intake: a longitudinal study. *International journal of epidemiology* 1996;25(5):1023-9.
11 601 [published Online First: 1996/10/01]
12 602 90. Koster-Rasmussen R, Siersma V, Halldorsson TI, et al. Missing portion sizes in FFQ--alternatives to use of
13 603 standard portions. *Public health nutrition* 2015;18(11):1914-21. doi: 10.1017/s1368980014002389
14 604 [published Online First: 2014/11/11]
15 605 91. Tjonneland A, Haraldsdottir J, Overvad K, et al. Influence of individually estimated portion size data on
16 606 the validity of a semiquantitative food frequency questionnaire. *IntJ Epidemiol* 1992;21(4):770-77.
17 607 92. Feskanich D, Rimm EB, Giovannucci EL, et al. Reproducibility and validity of food intake measurements
18 608 from a semiquantitative food frequency questionnaire. *Journal of the American Dietetic Association*
19 609 1993;93(7):790-6. [published Online First: 1993/07/01]
20 610 93. Hunter DJ, Sampson L, Stampfer MJ, et al. Variability in portion sizes of commonly consumed foods
21 611 among a population of women in the United States. *American journal of epidemiology* 1988;127(6):1240-
22 612 9. [published Online First: 1988/06/01]
23 613 94. Andersen V, Chan S, Luben R, et al. Fibre intake and the development of inflammatory bowel disease : A
24 614 European prospective multi-centre cohort study (EPIC-IBD). *Journal of Crohn's and Colitis*
25 615 2018;12(2):129.
26 616 95. Goldbohm RA, van 't Veer P, van den Brandt PA, et al. Reproducibility of a food frequency questionnaire
27 617 and stability of dietary habits determined from five annually repeated measurements. *European*
28 618 *journal of clinical nutrition* 1995;49(6):420-9. [published Online First: 1995/06/01]
29 619 96. Johnsen NF, Christensen J, Thomsen BL, et al. Physical Activity and Risk of Colon Cancer in a Cohort of
30 620 Danish Middle-Aged Men and Women. *European Journal of Epidemiology* 2006;21(12):877-84. doi:
31 621 10.1007/s10654-006-9076-z
32 622 97. uk biobank. Improving the health of future generations [Available from: <http://www.ukbiobank.ac.uk/>
33 623 accessed May 2018].
34 624 98. Andersen V, Vogel U. Dietary fibres and meat in relation to Colorectal Cancer. *Norske Gastroenterologisk*
35 625 *Forening-nytt* 2014(21):34-36.
36 626 99. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont
37 627 expansion and colitis in Il10^{-/-} mice. *Nature* 2012;487(7405):104-8. doi: 10.1038/nature11225
38 628 [published Online First: 2012/06/23]
39 629 100. Strober W. Vitamin A rewrites the ABCs of oral tolerance. *Mucosal immunology* 2008;1(2):92-5. doi:
40 630 10.1038/mi.2007.22 [published Online First: 2008/12/17]
41 631 101. Agmon-Levin N, Theodor E, Segal RM, et al. Vitamin D in systemic and organ-specific autoimmune
42 632 diseases. *Clinical reviews in allergy & immunology* 2013;45(2):256-66. doi: 10.1007/s12016-012-8342-y
43 633 [published Online First: 2012/12/15]
44 634 102. Kaulmann A, Bohn T. Carotenoids, inflammation, and oxidative stress--implications of cellular
45 635 signaling pathways and relation to chronic disease prevention. *Nutrition research (New York, NY)*
46 636 2014;34(11):907-29. doi: 10.1016/j.nutres.2014.07.010 [published Online First: 2014/08/20]
47 637 103. Ejsing-Duun M, Josephsen J, Aasted B, et al. Dietary gluten reduces the number of intestinal regulatory
48 638 T cells in mice. *Scandinavian journal of immunology* 2008;67(6):553-9. doi: 10.1111/j.1365-
49 639 3083.2008.02104.x [published Online First: 2008/05/15]
50 640 104. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3⁺ regulatory T cells. *Nature*
51 641 *reviews Immunology* 2011;11(2):119-30. doi: 10.1038/nri2916 [published Online First: 2011/01/27]

- 1
2
3
4 642 105. Pedros C, Duguet F, Saoudi A, et al. Disrupted regulatory T cell homeostasis in inflammatory bowel
5 643 diseases. *World journal of gastroenterology* 2016;22(3):974-95. doi: 10.3748/wjg.v22.i3.974 [published
6 644 Online First: 2016/01/27]
- 7 645 106. Yao CK, Muir JG, Gibson PR. Review article: insights into colonic protein fermentation, its modulation
8 646 and potential health implications. *Alimentary pharmacology & therapeutics* 2016;43(2):181-96. doi:
9 647 10.1111/apt.13456 [published Online First: 2015/11/04]
- 10 648 107. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. *Nature reviews Immunology*
11 649 2016;16(6):341-52. doi: 10.1038/nri.2016.42 [published Online First: 2016/05/28]
- 12 650 108. Desai MS, Seekatz AM, Koropatkin NM, et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the
13 651 Colonic Mucus Barrier and Enhances Pathogen Susceptibility. *Cell* 2016;167(5):1339-53.e21. doi:
14 652 10.1016/j.cell.2016.10.043 [published Online First: 2016/11/20]
- 15 653 109. Png CW, Linden SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa
16 654 augment in vitro utilization of mucin by other bacteria. *Am J Gastroenterol* 2010;105(11):2420-8. doi:
17 655 10.1038/ajg.2010.281 [published Online First: 2010/07/22]
- 18 656 110. Windey K, De Preter V, Louat T, et al. Modulation of protein fermentation does not affect fecal water
19 657 toxicity: a randomized cross-over study in healthy subjects. *PloS one* 2012;7(12):e52387. doi:
20 658 10.1371/journal.pone.0052387
- 21 659 111. Ijssennagger N, van der Meer R, van Mil SWC. Sulfide as a Mucus Barrier-Breaker in Inflammatory
22 660 Bowel Disease? *Trends in Molecular Medicine* 2016;22(3):190-99. doi: 10.1016/j.molmed.2016.01.002
- 23 661 112. Gibson GR, Macfarlane GT, Cummings JH. Sulphate reducing bacteria and hydrogen metabolism in the
24 662 human large intestine. *Gut* 1993;34(4):437-39. doi: 10.1136/gut.34.4.437
- 25 663 113. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature*
26 664 2011;474(7351):298-306. doi: 10.1038/nature10208
- 27 665 114. Cui J, Chen Y, Wang HY, et al. Mechanisms and pathways of innate immune activation and regulation
28 666 in health and cancer. *Human Vaccines & Immunotherapeutics* 2014;10(11):3270-85. doi:
29 667 10.4161/21645515.2014.979640
- 30 668 115. Jia W, Whitehead RN, Griffiths L, et al. Diversity and distribution of sulphate-reducing bacteria in
31 669 human faeces from healthy subjects and patients with inflammatory bowel disease. *FEMS*
32 670 *Immunology & Medical Microbiology* 2012;65(1):55-68. doi: 10.1111/j.1574-695X.2012.00935.x
33 671
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Hypothesis for effects of diet in relation to development of chronic inflammatory diseases (CID)

"Diet (meat⁹⁸, fibre⁹⁸, animal fat⁹⁹, n-3²⁷ and n-6 polyunsaturated fatty acids, vitamin A¹⁰⁰ and D¹⁰¹, carotenoids¹⁰², smoking, gluten¹⁰³) may affect the immune system^{104 105} either directly or indirectly via e.g. the activity and composition of the gut microbiome.^{106 107} The effect of low intake of fiber/high intake of red and processed meat is shown at left: In short, low intake of fibre (which could otherwise serve as a nutrient for the microbes) may lead to the microbial metabolism of mucus and to decrease of the intestinal mucus layer.^{58 108 109} A high intake of red and processed meat (containing organic sulphur and sulphate additives) may render the mucus layer penetrable to e.g. bacteria by reducing the disulphide bonds in the mucus network.^{8 106 110} Thus, microbes may reach the epithelium^{8 111 112} and activate the immune system.^{8 113 114} There is some support for such a mechanism in CID⁸, including findings of; high amounts of sulphate-reducing bacteria in IBD patients;^{8 112 115} association of high fibre intake with low risk of IBD among 170 776 participants from the prospective Nurses' Health Study I (NHSI)^{8 24}; and association of high intake of red meat and total protein and risk of developing inflammatory polyarthritis in the population-based prospective cohort of 25 630 participants from the European Prospective Investigation of Cancer in Norfolk (EPIC-Norfolk).^{8 36 37}Note. Figure from "Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine," by Christensen R, Heitmann BL, Andersen KW, et al., *BMJ Open* 2018;8:e018166. doi: 10.1136/bmjopen-2017-018166. Available at: <http://bmjopen.bmj.com/content/8/2/e018166>. Copyright 2018 by Vibeke Andersen.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and
2			sensitivity analyses
3			
4	Discussion		
5	Key results	18	Summarise key results with reference to study objectives
6	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or
7			imprecision. Discuss both direction and magnitude of any potential bias
8			
9	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,
10			multiplicity of analyses, results from similar studies, and other relevant evidence
11	Generalisability	21	Discuss the generalisability (external validity) of the study results
12			
13	Other information		
14	Funding	22	Give the source of funding and the role of the funders for the present study and, if
15			applicable, for the original study on which the present article is based
16			

17
18 *Give information separately for exposed and unexposed groups.

19
20
21 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and
22 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
23 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
24 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
25 available at <http://www.strobe-statement.org>.

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Impact of red meat, processed meat and fibre intake on risk of late onset chronic inflammatory diseases: a prospective cohort study on prognostic factors using the Danish "Diet, Cancer and Health" cohort (PROCID-DCH): Protocol for a prospective cohort study of prognostic factors and disease risk

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024555.R1
Article Type:	Protocol
Date Submitted by the Author:	08-Dec-2018
Complete List of Authors:	Rasmussen, Nathalie Fogh; Aarhus University, Faculty of Health Sciences; Hospital of Southern Jutland, Focused research unit for Molecular Diagnostic and Clinical Research, IRS-Center Sonderjylland Rubin, Katrine; OPEN - Odense Patient data Explorative Network, Department of Clinical Research, University of Southern Denmark, and Odense University Hospital, Odense, Denmark Stougaard, Maria; OPEN - Odense Patient data Explorative Network, Department of Clinical Research, University of Southern Denmark, and Odense University Hospital, Odense, Denmark Odense, DK Tjønneland, Anne; Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen Ø, Denmark/Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark Stenager, Egon; University of Southern Denmark, Department of Regional Health Research; Hospital of Southern Jutland, The Multiple Sclerosis Clinic of Southern Jutland (Sonderborg, Kolding, Esbjerg), Department of Neurology Lund Hetland, Merete; Rigshospitalet Glostrup, DANBIO Registry/Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics Glintborg, B.; Rigshospitalet Glostrup, DANBIO registry/Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics; Gentofte Hospital, Department of Rheumatology Bygum, Anette; Odense Universitetshospital, Department of Dermatology and Allergy Centre Andersen, Vibeke; Hospital of Southern Jutland, Focused research unit for Molecular Diagnostic and Clinical Research; Syddansk Universitet Det Sundhedsvidenskabelige Fakultet, institute og molecular medicine
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Dermatology, Neurology, Nutrition and metabolism, Rheumatology, Epidemiology

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords:	lifestyle, diet, chronic inflammatory diseases, disease risk, fibre, red meat

SCHOLARONE™
Manuscripts

1
2
3
4 1 **Abbreviated title:** Impact of red meat, processed meat and fibre on risk of late onset CID
5
6
7 2 **Impact of red meat, processed meat and fibre intake on risk of late onset**
8
9
10 3 **chronic inflammatory diseases: a prospective cohort study on prognostic**
11
12
13 4 **factors using the Danish "Diet, Cancer and Health" cohort (PROCID-DCH):**
14
15
16
17 5 *Protocol for a prospective cohort study of prognostic factors and disease risk*
18
19
20

21 6 Nathalie Fogh Rasmussen^{1,8}, Katrine Hass Rubin², Maria Stougaard², Anne Tjønneland³, Egon Stenager⁴,
22
23 7 Merete Lund Hetland⁵, Bente Glintborg^{5,6}, Anette Bygum⁷, Vibeke Andersen^{8,9,10}
24

25 8 ¹Faculty of Health Sciences, Aarhus University, Aarhus, Denmark

26 9 ²OPEN - Odense Patient data Explorative Network, Department of Clinical Research, University of Southern Denmark,
27 10 and Odense University Hospital, Odense, Denmark

29 11 ³Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen Ø, Denmark/Department of Public
30 12 Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

32 13 ⁴Department of Regional Health Research, University of Southern Denmark, Odense C, Denmark/The Multiple Sclerosis
33 14 Clinic of Southern Jutland (Sonderborg, Kolding, Esbjerg), Department of Neurology, Hospital of Southern Jutland,
34 15 Sonderborg, Denmark

36 16 ⁵The DANBIO registry/Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine
37 17 Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark

39 18 ⁶Department of Rheumatology, Herlev and Gentofte University Hospital, Hellerup

41 20 ⁷Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark

43 22 ⁸Focused research unit for Molecular Diagnostic and Clinical Research, IRS-Center Sonderjylland, Hospital of Southern
44 23 Jutland, Aabenraa, Denmark

46 25 ⁹Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark

48 27 ¹⁰Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark

50 28
51 29 **Correspondence:** Vibeke Andersen, Focused Research Unit for Molecular Diagnostic and Clinical Research
52
53 30 (MOK), IRS-Center Sonderjylland "Forskningshuset", Hospital of Southern Jutland, Kresten Philipsens Vej
54
55 31 15 F, 6200 Aabenraa, Denmark, email: vandersen@health.sdu.dk
56
57
58
59
60

32 ABSTRACT

33 **Introduction:** Chronic inflammatory diseases, CIDs, (Crohn's disease, ulcerative colitis, psoriasis,
34 psoriatic arthritis, rheumatoid arthritis, and multiple sclerosis) are diseases of the immune system
35 that have some shared genetic and environmental predisposing factors, but still few studies have
36 investigated the effects of lifestyle on disease risk of several CIDs. The primary aim of this
37 prospective cohort study is to investigate the impact of fibre, red meat, and processed meat on
38 risk of late onset CID, with the perspective that results of this study can contribute in supporting
39 future diet recommendations for effective personalized prevention.

40 **Methods and analysis:** The study will use data from 57,053 persons from the prospective Danish
41 cohort study "Diet, Cancer and Health" together with National Health Registry data. The follow-
42 up period is from December 1993 to May 2018. Questionnaire data on diet and lifestyle were
43 collected at entry to the "Diet, Cancer and Health" study. The outcome CID is defined as having a
44 diagnosis of one of the CIDs registered in the National Patient Registry or, for multiple sclerosis,
45 in the Danish Multiple Sclerosis Registry during follow-up AND being treated with a drug used
46 for the specific disease. The major outcome of the analyses will be to detect variability in risk of
47 late onset of any CID and, if power allows, disease risk of late onset of each CID diagnosis
48 between persons with different fibre and red meat, and processed meat intake. The outcome will
49 be adjusted for age, sex, BMI, physical activity, energy, alcohol, fermented dairy products,
50 education, smoking status, hormone replacement therapy, and comorbidity.

51 **Ethics and dissemination:** The study is approved by the Danish Data Protection Agency (2012-58-
52 0018). The core study is an open register-based cohort study. The study does not need approval

1
2
3
4 53 from the Ethics committee or Institutional Review Board by Danish law. Study findings will be
5
6
7 54 disseminated through peer-reviewed journals, patient associations and presentations at
8
9 55 international conferences.
10

11
12
13 56 **Keywords:** lifestyle; diet; chronic inflammatory diseases; disease risk; fibre; red meat
14

15 16 **Strengths and limitations of this study** 17

18 19 20 Strengths:

- 21
22
23 • The linkage to Danish national registers will ensure almost complete follow-up of the
24 study population, as the Danish registries are considered of high validity and
25
26 completeness
27
28
- 29
30
31 • The big sample size will enable a sufficient power of the total late onset CID disease
32 group even when taking loss to emigration and competing risk of death into account
33
34
- 35
36
37 • The study includes several chronic inflammatory diseases
38
39

40 41 42 Limitations:

- 43
44
45 • Risk of low specificity of the diagnostic codes and treatment codes as criteria for
46 identifying late onset CID cases
47
48
- 49
50
51 • Prospective studies including younger age groups are necessary to reveal the
52 generalizability of the results
53
54

55
56
57 57 **Trial Registration details:** *ClinicalTrials.gov identifier: NCT03456206*
58
59
60

58 INTRODUCTION

59 The CIDs can be considered as systemic diseases which primarily affect one organ such as
60 the intestine (inflammatory bowel disease (IBD): Crohn's disease (CD) and colitis ulcerosa (UC)),
61 skin (psoriasis (PsO)), joints (rheumatoid arthritis (RA) and psoriatic arthritis (PsA)), or the brain
62 (multiple sclerosis (MS)).

63 The peak of disease-onset is in the adult phase of life. The diseases have a large impact on the
64 patients and their families' quality of life due to lack of causative treatment, and on the society due
65 to absence from work and on health care economy due to lack of preventative measures.¹⁻⁷ The
66 CIDs have a high prevalence, with IBD and MS affecting respectively 0.5% and 0.1% of the
67 population in the Western world.⁸⁻¹² Studies from across the world have reported prevalence
68 estimates of RA and PsO ranging from 0.3%–1.0% and 0.7%-3.2% respectively,^{2 8 13-15} while the
69 prevalence of PsA is estimated as 0.04-0.25% across countries.^{14 16} Furthermore, one-third of RA
70 patients are diagnosed at >60 years of age¹⁷ and the incidence of late-onset IBD and MS have been
71 reported to increase.^{18 19}

72 The CIDs have some shared genetic²⁰⁻²⁴ and environmental (e.g. smoking, gut microbiome)
73 predisposing factors, and causes of the high incidence and prevalence point to such environmental
74 factors.^{8 25-40} Therefore, further research of the associations between potential modifiable
75 environmental risk factors and risk of CID is important.

76 Evidence-based research

77 It has been demonstrated that a high level of red meat consumption is a risk factor for the
78 development of inflammatory polyarthritis (including RA).^{39 40} A high fibre intake has been
79 associated with low risk of IBD.²⁷ Furthermore, several studies of the impact of dietary factors on
80 MS point towards an impact of meat preservation such as smoking or addition of nitrites.⁴¹⁻⁴⁴

1
2
3
4 81 Studies have also suggested other lifestyle factors such as physical activity,⁴⁵⁻⁴⁷ body mass index
5
6
7 82 (BMI),^{1 47-49} smoking status,⁵⁰⁻⁵⁶ and other dietary factors such as alcohol,^{1 57-59} dairy products,³⁸ and
8
9 83 glycaemic index^{60 61} to be associated with CIDs. Furthermore, studies have shown that the
10
11 84 interactions among the microbiota, female sexual hormones, and immunity are associated with the
12
13
14 85 development of autoimmune diseases.⁶²
15
16

17 86 There are many potential mechanisms whereby environment such as diet may affect the
18
19 87 immune system (Figure 1). Recently, we provided the hypothesis that intake of high fibre/low red
20
21
22 88 and processed meat may protect against CID.⁶¹ Figure 1 presents a model, proposed in a previous
23
24
25 89 study,⁸ whereby a diet high in meat and low in fibres may impact inflammation.
26
27

90 **FIGURE 1**

91 **Aims and hypotheses**

92 Based on previous evidence, we set out to prospectively identify dietary factors that have an
93 impact on disease risk of late onset CID.
94

95 The primary aim of this prospective cohort study is to investigate the impact of fibre, red
96 meat, and processed meat on disease risk outcomes of late onset CID in the “Diet, Cancer and
97 Health” (DCH) cohort. The overall perspectives are that results from this study will be
98 contributing in supporting future diet recommendations for effective personalized prevention of
99 individuals identified to be at high risk.
100

101 The main hypothesis is that “the risk of late onset CID will be significantly lower among
those with a high fibre/low red meat, and processed meat intake compared to those with a low
fibre/high red meat and processed meat intake.” The hypothesis is illustrated in figure 1.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Based on previous research on a shared etiology in CIDs we hypothesize that “the suggested association between high fibre/low red meat, and processed meat intake and risk of developing CID is applicable for each of the CID diagnoses.”

The secondary aim of this prospective cohort study is to investigate whether risk of late onset CID in the DCH cohort is affected by other dietary and lifestyle differences, and therefore to adjust for the potential confounders: age, sex, BMI, physical activity, energy, alcohol intake, intake of fermented dairy products, education after basic school, hormone replacement therapy (HRT), smoking status, and comorbidity.

METHODS AND ANALYSES

Design and setting

This study is an observational study using prospective registry follow-up data. We will use the Danish cohort “Diet, Cancer and Health”, and the follow-up period will be from the date of entry in the DCH cohort (between December 1993 and May 1997) until May 2018.

The DCH Study is an ongoing Danish cohort study designed to investigate the relation between diet, lifestyle, and disease risk.⁶³ The cohort consists of 57,053 persons, recruited between December 1993 and May 1997. All the subjects (50 to 64 years of age) gave detailed information on diet (food frequency questionnaire (FFQ)) and other lifestyle data. Questionnaire data on diet and lifestyle were collected at study entry.⁶³ Data from the DCH cohort will be combined with Danish Health registries (the National Patient Registry (NPR), the Danish Civil Registration System (CRS), The Danish National Prescription Registry (DNPR) and the Danish Multiple Sclerosis Registry (DMSR)).

Participant characteristics and eligibility criteria

Criteria for inclusion: The population to be studied include participants in the DCH cohort.⁶³

In short, the criteria for invitation to the DCH cohort were: age between 50 and 64, born in Denmark, and no diagnosis of cancer registered in the Danish Cancer Registry. All persons fulfilling these criteria and living in the areas of Copenhagen and Aarhus were invited.⁶³

Criteria for exclusion: Participants registered in NPR or DMSR with a CID primary diagnosis from a department with relevant area of specialization in the period between 1977 and entry to the DCH cohort will be excluded regardless of whether the person receive medical treatment for CID or not.

The Danish health Registries

We will extract data from the four national registries in those time periods that is possible for each registry; NPR from 1977-2018, CRS from 1977-2018, DNPR from 1994-2018, and DMSR from 1977-2018. An overview of the information obtained from the different registries is presented in **table 1**.

Table 1. Overview of registry information

Variable	Definition	Registry	Time period
CPR	Civil Registration Number	CRS	1977-2018
ICD-10 code*	International Classification of Diseases	NPR	1994-2018
ICD-8 code*	International Classification of Diseases	NPR	1977-1993
Medication (ATC code)	Anatomical Therapeutic Chemical classification (ATC) code	DNPR	1994-2018
Treatment code	Medical treatment classification code	NPR	1994-2018
Department with relevant area of specialization	Medical and gastroenterological department (IBD), medical and rheumatological department (RA, PsA), Medical and dermatological department (PsA, PsO)	NPR	1977-2018
ICD-8 and ICD-10 codes for MS	Diagnostic codes for multiple sclerosis	DMSR	1977-2018

*ICD-8 and ICD-10 codes in the period 1977-1997 will be used to define CID diagnosis

Abbreviations: The Danish Civil Registration System (CRS); National Patient Registry (NPR); Danish National Prescription Registry (DNPR); Danish Multiple Sclerosis Registry (DMSR);

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The NPR will be used to identify patients with CID during follow-up and, in addition, patients with CID before study entry. The NPR contains data on all patients admitted to Danish hospitals since 1977. The register covers both inpatient and outpatient records and indicates the main medical reason for diagnostic procedures or treatment (since 1971 according to the eighth version and 1994 according to the tenth version of the International Classification of Diseases (ICD-8 and ICD-10)). ICD-8 and ICD-10 codes will be used to identify cases diagnosed before entry to the DCH cohort study. Information on the departments with the relevant areas of specialization will be obtained from the NPR and used to identify cases as described in the data analysis section.

The DMSR will be used to identify patients with MS during follow-up, and in addition, patients with MS before study entry.

The DNPR will be used to obtain information on the medical treatment according to the Anatomical Therapeutic Chemical classification (ATC) code.

From the CRS we will extract follow-up information on civil status, death and immigration.

Data will be linked by the unique identification number assigned to all residents in Denmark at birth or first immigration which provides a unique opportunity to link information about diagnoses, medications, etc. at the individual level.

Outcome and exposures

Outcome: In this study, the outcome *late onset CID* is defined as one of the following diseases; CD, UC, PsO, PsA, RA, or MS. This outcome is defined by fulfilling the following two criteria: 1) having the CID disease in NPR (except MS) from a department with relevant area of specialization,

or in the DMSR (MS) during the follow-up period AND 2) being treated (irrespective of the number of treatments) with a drug used for the specific disease, and the treatment being registered either in the DNPR or from a department with relevant area of specialization (criterion 2 will not apply to MS). The outcome late onset CIDs with the associated ICD-8 and ICD-10 codes and the ATC codes in DNPR and treatment codes in the NPR are specified in **table 2**. The date and year of the diagnosis is defined as the date and year of the diagnosis in NPR and/or DMSR. If a patient has several CID diseases, only time to the first diagnosis will be included in the analyses.

Table 2. Specification of outcome CIDs with associated diagnostic- and treatment codes

Chronic Inflammatory Disease (CID)	Diagnostic code (NPR)		Medical treatment (DNPR and NPR)		Depart. with relevant area of specialization
	ICD-8*	ICD-10	ATC code (DNPR)***	Treatment code (NPR)***	
Crohn's disease (CD)	563.01, 563.02	K50.0-50.9	L04AB02 L04AB04 L04AB06 L04AB05 L04AA33	BOHJ18A1 BOHJ18A3 BOHJ18A4 BOHJ18A5	Gastroenterology, Internal Medicine
Ulcerative colitis (UC)	563.09, 563.19	K51.0-51.9	L04AX01 L04AX03 L01BB02 A07E	BOHJ26 BOHJ19H4	Gastroenterology, Internal Medicine
Chronic polyarthritis, including RA	712.19, 712.29, 712.39, 712.59	M05.9, M06.0	L04AX01 L04AX03	BWHA115 BLHM2 BWHB83	Rheumatology, Internal Medicine
Psoriatic arthritis (PsA)	696.09	M09.0, M07.3, M46.8+M07.2	L04AA13 P01BA02	BOHJ18	Rheumatology, Internal Medicine
Psoriasis (PsO)	696.10, 696.19	L40.0-40.9	D05AX02 D05BB02 D05B L04AA32 L04AB01-02 L04AB04 L04AC05 L04AC10 L04AC13 L04AD01 L04AX03	BWHA115 BOHJ20 BNHC BOHJ18A1-3 BOHJ18B3 BOHJ18B5	Dermatology, Internal Medicine
Multiple sclerosis (MS)	734.0-9**	G35.9**	Not used	Not used	Danish Multiple Sclerosis Registry

*ICD-8 and ICD-10 codes will be used to define participants with a CID diagnosis.

**ICD-8 and ICD-10 codes for MS will be extracted from the Danish Multiple Sclerosis Registry (DMSR)

***These ATC and treatment codes for CD and UC are used by the Danish National Registry for Biological Therapy in Inflammatory Bowel Disease (BIO-IBD)⁶⁴

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Exposure and possible confounders: Information on exposure in this study is defined as high fibre intake and high red meat, and processed meat intake, and also other dietary and lifestyle factors.

In the DCH study, information on diet and lifestyle exposure were collected at enrollment using questionnaires as has been described in details elsewhere.⁶³ In short, in the FFQ diet consumption was assessed in 12 categories of predefined responses, ranking from “never” to “eight times or more per day over the past 12 months”. The daily intake was then calculated by FoodCalc.⁶³ Both intake of dietary fibre and red meat and processed meat were measured as continues variable in g/day. The initially collected data on diet and lifestyle exposure of the DCH cohort is used as the baseline information on exposure in this study.

Information on dietary and lifestyle exposures used for this study is specified in **table 3**. Fibres, red meat, and processed meat are defined based on the classification of the food items in the DCH study,⁶³ and with inspiration from other studies using dietary data from the DCH cohort.⁶⁵⁻⁶⁷ Red meat is defined as fresh and minced meat (unprocessed) from beef, veal, pork, and lamb and excluding poultry, fish, and eggs. Processed meat consists of red meat, poultry and fish items that have undergone processing such as smoking, salting or curing. This includes various kinds of sausages, salami, smoked or cooked ham, poultry or fish, other cold cuts, bacon and liver pate. Poultry includes chicken and turkey both unprocessed and processed, such as various cold cuts of chicken and turkey. Fish includes all unprocessed and processed fish as well as shellfish. Total meat is defined as the total of red (unprocessed) meat, red processed meat together with poultry and fish.⁶⁵⁻⁶⁷ Fibres are defined as fibres from fibrous food items from the FFQ.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

193 Information on possible confounders will also be obtained from the questionnaire data at
194 enrollment in relation to sex, age, education after basic school, BMI, physical activity, energy, HRT,
195 comorbidity, smoking status, alcohol intake, and also intake of fermented dairy products. The
196 Charlsons comorbidity index⁶⁸ will be used to classify comorbidity among the study participants.
197 ICD-8 and ICD-10 codes from the NPR will be used to calculate the Charlson score, using the
198 updated Charlson comorbidity index.⁶⁹

Table 3. Specification of exposures and overall food groups and lifestyle factors

Variable	Definition (unit)
<i>Diet</i>	
Total energy intake	kJ/day
Total meat	g/day
Red meat	g/day
Red, processed meat	g/day
Fish (fresh and processed)	g/day
Poultry (fresh and processed)	g/day
Total dietary fibre intake	g/day
Legumes	g/day
Vegetables	g/day
Fruits	g/day
Cereals	g/day
Dairy products	g/day
<i>Lifestyle factors</i>	
Alcohol intake	units of alcohol/week*
Smoking status	yes/no
Former smoker	
Current smoker	
Never smoker	
MET-score (physical activity)	hours/week
Body Mass Index (BMI)	kg/cm ²
Highest education after basic school	yes/no
Vocational education	
Higher education 1-2 years	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Higher education 3-4 years

Higher education > 4 years

Co-morbidity (Charlson comorbidity index) index score

Hormone replacement therapy (HRT) yes/no

*One unit of alcohol is defined as 12 grams of pure alcohol

Primary exposure variable: The primary exposure variables will be analyzed in tertiles. Based on the hypothesis that the risk of CID and late onset CID will be lower among those with a high fibre/low red meat, and processed meat intake compared to those with a low fibre/high red meat, and processed meat intake, it is expected that:

- The upper tertile of the sample (33.3% of the total sample), based on the ratio of fibre/meat intake, is associated with lower risk of CID and late onset CID.
- The lower tertile of the sample (33.3% of the total sample) with respect to intake of red meat and processed meat and the upper tertile of the sample (33.3% of the total sample) with respect to intake of dietary fibres are independently associated with lower risk of CID and late onset CID, and a potential interaction between them may further lower the risk of CID and late onset CID.

Other (exploratory) exposure variables:

- Other dietary and lifestyle factors independently or combined will be analysed, and are presented in table 3.

Statistical analysis plan

The data obtained from this study will be used to investigate our ability to predict risk of late onset CID, based on whether a diet high in fibre and low in red meat, and processed meat is a

1
2
3
4 217 predictive factor. Furthermore, data on other lifestyle factors and dietary factors obtained from the
5
6
7 218 FFQ will be used to investigate whether these factors potentially could give risen to confounding
8
9 219 of the association between fibre/meat intake and risk of late onset CID.
10

11
12 220 Descriptive analyses for categorical variables will be presented as frequencies, and
13
14 221 differences between late onset CID cases and non-cases will be evaluated by Chi-square test.
15
16
17 222 Continuous variables will be tabulated as medians (with quartiles, Q1 and Q3) and nonparametric
18
19 223 tests on the equality of medians will be used to test for differences between groups. P-values below
20
21
22 224 0.05 will be considered statistically significant. Negative binomial regression will be applied to
23
24 225 calculate incidence rates per 1,000 patient years and incidence rate ratios (IRR) between exposures.
25
26
27 226 To investigate the risk of and time to CID diagnosis the Fine-Gray competing risk regression
28
29 227 model will be applied, and thus competing risk of death will be taken into account while handling
30
31
32 228 emigration as censoring and reporting cumulative incidences and sub-hazard ratios (SHR) and the
33
34 229 corresponding p-values for late onset CID associated with specified food substitutions.
35
36
37 230 Regressions will be carried out as both crude regressions, only including the exposure, and
38
39 231 adjusted for age, sex, lifestyle factors and selected comorbidities. Sensitivity analyses of the
40
41
42 232 outcome variable and use of medication will be carried out.

43
44 233 Logistic regression will be conducted to examining the association between fibre/meat intake
45
46 234 and already being diagnosed with a CID diagnose. Analyses will be conducted using Stata version
47
48
49 235 15.⁷⁰

50
51 236 If power of each of the disease groups allows, there will be conducted sub-analyses on each
52
53
54 237 of the late onset CID diagnoses separately with the overall aim of testing if the hypothesized
55
56 238 association between diet factors and development of late onset CID is applicable for all the late
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

239 onset CIDs or if some of the late onset CIDs deviate from this association. Moreover, analyses
240 omitting MS from the overall definition of CID, will be performed.

241 Information on the departments with the relevant areas of specialization will be used to
242 evaluate the robustness of the diagnosis codes from the NPR and to identify the cases as we will
243 only accept cases that have a diagnosis from a relevant department. The DMSR is highly
244 validated,⁷¹ and data from the registry will be used to ensure complete follow-up of valid
245 diagnoses of MS.

246 *Power considerations, late onset CID:* The age-adjusted (age between 45-69) incidences per
247 100,000 years of the CIDs in Denmark are 10.1-10.6 for CD⁷²; 27.5-32.7 for UC⁷²; 200-225 for PsO¹⁵;
248 28-35 for PsA¹⁶; 4.4-7.5 for MS^{19 73-76}; and 28.1-57.6 for RA^{77 78}. In the cohort of approximately 57,000
249 participants and a follow-up period of approximately 20 years, these incidences correspond to an
250 estimate of approximately 2,000 cases of CID in the cohort. To estimate the power of the study we
251 therefore expect approximately 2,000 cases of CID, i.e. an incidence of about 3% and about one
252 third of the cohort in the low risk and two thirds in the high risk exposure. Assuming a fixed
253 follow-up of 20 years and a relevant effect size of 2% CID risk in the low risk exposure compared
254 to 3% in the high risk exposure this would require 11,667 participants to obtain a power of 0.90 in
255 an (unadjusted) Chi-squared-test. Hence with a total cohort size of approximately 57,000, this
256 should ensure a sufficient power even when taking loss to emigration and competing risk of death
257 (resulting in less than 20 years follow-up for some participants) into account.

258 Patient and Public Involvement

259 This study is register based and there will be no patients or public involvement in the study.

260 Strengths and limitations of the study

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

261 A strength of this study is that it is not limited to one disease, as it includes several CIDs.
262 Another strength is that the linkage to Danish Health registries will ensure almost complete
263 follow-up of the study population, as the Danish Health registries are considered the
264 internationally most comprehensive with high validity.⁷⁹⁻⁸² Furthermore, in this study, we have
265 chosen very restrictive criteria for defining the late onset CID cases by requiring that cases fulfill
266 both diagnostic and treatment criteria, or that the cases were registered in the DMSR. This
267 approach ensures that a high proportion of the identified cases really had late onset CID.
268 Therefore, some “real” CID cases might not have been identified, hence lowering the sensitivity.⁷¹
269 ^{83 84}

270 A possible limitation of this study could have been the validity of the diagnostic codes from
271 the NPR and the treatment codes from the DNPR as criteria for identifying late onset CID cases.^{71 83}
272 But, as described in the analysis plan this potential limitation will be sought eliminated by using
273 the information on the hospital departments, and for MS, using the DMSR for identifying MS
274 cases. In addition, usually dietary habits do not change much during life. Therefore, the exposure
275 time to the diet is long in 50+ age group and a possible impact of diet is possibly located much
276 earlier in life. Therefore, we have included an analysis among those who at entry to the DCH
277 cohort already had a CID diagnosis to examine if their low/high intake of dietary fibre, red meat
278 and processed meat is associated with having CID. We are well aware that such an analysis might
279 be impacted by bias by indication and that the results should be interpreted with this in mind.

280 The FFQ applied in the present study has been used in the large, European prospective
281 cohort study “The European Prospective Investigation into Cancer and Nutrition” (EPIC),^{85 86} and
282 it has been used and evaluated in the Danish population, with results that demonstrate
283 consistency.⁸⁷⁻⁸⁹ However, the FFQ is not without limitations, with respect to the lack of

1
2
3
4 284 information on portion sizes^{90 91} or to underestimation and overestimation of intake of unhealthy
5
6
7 285 and healthy food.⁹² Any imprecision of the FFQ due to standardized portion sizes or incorrect
8
9 286 reporting of food intake, will lead to large confidence intervals, which potentially can lead to null
10
11
12 287 results.⁸ On the other hand, studies suggest that specification of a standard portion size may not
13
14 288 introduce a large error in the estimation of food and nutrient intake.⁹³ Furthermore, the FFQ has
15
16
17 289 been validated as being appropriate for use in studies that examine relationships between diet and
18
19 290 risk of disease.⁹²

21
22 291 Another limitation of this study is the validity of the information on exposure as this
23
24 292 information is collected at study entry, which potentially can be several years before any outcome
25
26
27 293 appears, and measurement error in the FFQ may occur if the participants change their diet over
28
29 294 time. Furthermore, there is a potential risk of recall bias according to the information on exposure,
30
31
32 295 as this information relies on the participants' ability to recall their dietary intake. In this study,
33
34 296 however, it is expected that dietary and lifestyle patterns among adults are relatively stable over
35
36
37 297 time, based on other longitudinal studies that showed minimal temporal changes.^{94 95}

39 298 The MET-score is an accepted standard measure of physical activity.⁹⁶ However, the
40
41
42 299 weaknesses of the MET-score include a risk of adding random variation by applying an assumed
43
44 300 intensity to include activities. Another weakness of the MET-score is the implicit assumption that
45
46
47 301 the intensity aspect of physical activity is important for development of disease.⁹⁶

49 302 The study population in this study is based on a cohort of middle-aged women and men
50
51 303 living in urban areas. This could reduce the generalizability of study findings, as the incidence of
52
53
54 304 CID diagnoses could be different for younger persons and persons from rural areas.

56 305 The disease groups may be heterogeneous regarding dietary and lifestyle factors. This study
57
58
59 306 may not capture every dietary and lifestyle difference between the disease groups, due to
60

1
2
3
4 307 insufficient power of each disease group, as described in the analysis plan. Replication of the
5
6
7 308 results in other well-characterized populations using prospectively sampled dietary data will
8
9 309 minimize the risk of potential type 2 errors. Study results should preferably be replicated in
10
11
12 310 cohorts in other countries and other age groups for further evaluation of the robustness of the
13
14 311 results.

18 312 **Project organisation**

21 313 This registry study is a cross-disciplinary collaboration that includes clinical specialists within
22
23
24 314 neurology, dermatology, rheumatology, inflammatory bowel diseases, prospective cohort study
25
26 315 design, and clinical registries.

30 316 **Perspectives**

33 317 We anticipate that the PROCID-DCH study will reveal factors of importance, including whether
34
35
36 318 the diet is likely to interfere with the disease risk of late onset CID.

39 319 The perspective is that significant results from this study will be sought replicated in other
40
41
42 320 cohorts such as the EPIC-IBD⁸⁵ and UK biobank⁹⁷ with high-quality prospective lifestyle data.

44 321 Successful replication indicates the robustness of the findings which is an important step on the
45
46
47 322 road to developing clinical tools for effective personalized prevention of individuals at high risk.

50 323 **Dissemination of results to the public and scientifically**

53 324 Target journals include international journals within internal medicine. In addition to the scientific
54
55
56 325 reporting of results, major findings with translational implications will also be communicated to
57
58 326 categories of both health professionals, and targeted stakeholders including public health
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

327 policymakers, and to the general public through various media and news activities. Intellectual

328 Property Rights (IPRs) to discoveries based upon the outlined research belong to the University of

329 Southern Denmark.

330 **Ethics**

331 This is an open register-based cohort study. The study does not need approval from the local

332 Ethics committee or Institutional Review Board by Danish law. The study was approved by the

333 Danish Data Protection Agency (2012-58-0018).

334 **Funding**

335 This work is supported by Region of Southern Denmark grant number [17/33849] (Vibeke

336 Andersen), and the Danish Rheumatism Association (R150-A4434-B760, Vibeke Andersen).

337 **Author Contributions:**

338 VA conceived of the presented idea and achieved funding. AT (diet and environmental factors,

339 epidemiology) designed the cohort, collected the data and made the data available for the present

340 project. NFR, KHR, MS and VA wrote the first draft and contributed to the further preparation and

341 final adjustments of the protocol. According to their respective specialization, all other authors, ES

342 (multiple sclerosis), MLH (rheumatology), BG (rheumatology) and AB (psoriasis) contributed to

343 the project. All authors discussed the results and contributed to the final manuscript.

344 **Conflicts of Interest:**

345 BG declares to have received research funding from Abbvie, Biogen, Pfizer. MLH declares to have

346 received research funding from BMS, MSD, Pfizer, Biogen, Samsung, CellTrion, Lilly, Novartis. AB

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

347 has participated in development of educational material for Biogen. All other authors declare no
348 conflict of interest.

For peer review only

FIGURE LEGEND**Figure 1. Hypothesis for effects of diet in relation to development of chronic inflammatory diseases (CIDs)**

Diet (meat⁹⁸, fibre⁹⁸, animal fat⁹⁹, n-3³⁰ and n-6 polyunsaturated fatty acids, vitamin A¹⁰⁰ and D¹⁰¹, carotenoids¹⁰², smoking, gluten¹⁰³) may affect the immune system^{104 105} either directly or indirectly via e.g. the activity and composition of the gut microbiome.^{106 107} The effect of low intake of fibre/high intake of red and processed meat is shown at left: In short, low intake of fibre (which could otherwise serve as a nutrient for the microbes) may lead to the microbial metabolism of mucus and to decrease of the intestinal mucus layer.^{61 108 109} A high intake of red and processed meat may render the mucus layer penetrable to e.g. bacteria by reducing the disulphide bonds in the mucus network.^{8 106 110} Thus, microbes may reach the epithelium^{8 111 112} and activate the immune system.^{8 113 114} There is some support for such a mechanism in chronic inflammatory diseases (CID)⁸, including findings of; high amounts of sulphate-reducing bacteria in inflammatory bowel disease (IBD) patients;^{8 112 115} association of high fibre intake with low risk of IBD among 170 776 participants from the prospective Nurses' Health Study I^{8 27}; and association of high intake of red meat and total protein and risk of developing inflammatory polyarthritis in the population-based prospective cohort of 25 630 participants from the European Prospective Investigation of Cancer in Norfolk.^{8 39 40}

Note. Figure from "Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine," by Christensen R, Heitmann BL, Andersen KW, et al., *BMJ Open* 2018;8:e018166. doi: 10.1136/bmjopen-2017-018166. Available at: <http://bmjopen.bmj.com/content/8/2/e018166>. Copyright 2018 by Vibeke Andersen.

Reference list

1. Amato M, Derfuss, T, Hemmer, B, Liblau, R, Montalban, X, Soelberg, PS, Miller, DH. Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. *Multiple Sclerosis Journal* 2017;1-14. doi: doi.org/10.1177/1352458516686847
2. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *The Journal of investigative dermatology* 2013;133(2):377-85. doi: 10.1038/jid.2012.339 [published Online First: 2012/09/28]
3. Baumgart DC, Carding SR. Gastroenterology 1: Inflammatory bowel disease: cause and immunobiology. *The Lancet* 2007;369(9573):1627.
4. Baumgart DC, Sandborn WJ. Gastroenterology 2: Inflammatory bowel disease: clinical aspects and established and evolving therapies. *The Lancet* 2007;369(9573):1641.
5. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. *The Journal of clinical investigation* 2007;117(3):514-21. doi: 10.1172/JCI30587
6. Taurog JD, Chhabra A, Colbert RA. Ankylosing Spondylitis and Axial Spondyloarthritis. *The New England journal of medicine* 2016;374(26):2563-74. doi: 10.1056/NEJMra1406182
7. Löfvendahl S, Theander E, Svensson Å, et al. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. *PloS one* 2014;9(5):e98024. doi: 10.1371/journal.pone.0098024
8. Christensen R, Heitmann BL, Andersen KW, et al. Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine. *BMJ open* 2018;8(2):e018166. doi: 10.1136/bmjopen-2017-018166 [published Online First: 2018/02/14]
9. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012;142(1):46-54.e42; quiz e30. doi: 10.1053/j.gastro.2011.10.001 [published Online First: 2011/10/18]
10. Leray E, Moreau T, Fromont A, et al. Epidemiology of multiple sclerosis. *Revue neurologique* 2016;172(1):3-13. doi: 10.1016/j.neurol.2015.10.006
11. Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. *Neurology* 2014;83(11):1022-4. doi: 10.1212/wnl.0000000000000768 [published Online First: 2014/09/10]
12. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *The Lancet* 2017;390(10114):2769-78. doi: 10.1016/S0140-6736(17)32448-0
13. WHO. Chronic Diseases and Health Promotion 2017 [Available from: <http://www.who.int/chp/topics/rheumatic/en/>].
14. Poddubnyy D, Rudwaleit M. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. *Expert opinion on drug safety* 2011;10(4):655-73. doi: 10.1517/14740338.2011.581661 [published Online First: 2011/05/11]
15. Egeberg A, Skov L, Gislason GH, et al. Incidence and Prevalence of Psoriasis in Denmark. *Acta dermato-venereologica* 2017;97(7):808-12. doi: 10.2340/00015555-2672 [published Online First: 2017/04/19]
16. Egeberg A, Kristensen LE, Thyssen JP, et al. Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. *Annals of the rheumatic diseases* 2017;76(9):1591-97. doi: 10.1136/annrheumdis-2016-210963 [published Online First: 2017/05/10]
17. Olivieri I, Palazzi C, Peruz G, et al. Management Issues with Elderly-Onset Rheumatoid Arthritis: An Update. *Drugs & Aging* 2005;22(10):809-22. doi: 10.2165/00002512-200522100-00002
18. Taleban S, Colombel JF, Mohler MJ, et al. Inflammatory bowel disease and the elderly: a review. *Journal of Crohn's & colitis* 2015;9(6):507-15. doi: 10.1093/ecco-jcc/jjv059 [published Online First: 2015/04/15]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

19. Koch-Henriksen N, Thygesen LC, Stenager E, et al. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. *Neurology* 2018;90(22):e1954-e63. doi: 10.1212/wnl.0000000000005612 [published Online First: 2018/05/04]
20. Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nature genetics* 2013;45(11):1353-60. doi: 10.1038/ng.2770 [published Online First: 2013/10/01]
21. Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. *Nature genetics* 2016;48(5):510-8. doi: 10.1038/ng.3528 [published Online First: 2016/03/15]
22. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet* 2011;43(3):246-52. doi: 10.1038/ng.764 [published Online First: 2011/02/08]
23. Ellinghaus D, Zhang H, Zeissig S, et al. Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. *Gastroenterology* 2013;145(2):339-47. doi: 10.1053/j.gastro.2013.04.040 [published Online First: 2013/04/30]
24. Goyette P, Boucher G, Mallon D, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. *Nature genetics* 2015;47(2):172-9. doi: 10.1038/ng.3176 [published Online First: 2015/01/07]
25. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. *Gastroenterology* 2012;142(3):482-9. doi: 10.1053/j.gastro.2011.11.040 [published Online First: 2011/12/14]
26. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. *Gut* 2014;63(5):776-84. doi: 10.1136/gutjnl-2013-305304 [published Online First: 2013/07/06]
27. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A Prospective Study of Long-term Intake of Dietary Fiber and Risk of Crohn's Disease and Ulcerative Colitis. *Gastroenterology* 2013;145(5):970-77. doi: 10.1053/j.gastro.2013.07.050
28. Ananthakrishnan AN, Khalili H, Song M, et al. Zinc intake and risk of Crohn's disease and ulcerative colitis: a prospective cohort study. *International journal of epidemiology* 2015;44(6):1995-2005. doi: 10.1093/ije/dyv301 [published Online First: 2015/11/08]
29. Ananthakrishnan AN, Khalili H, Song M, et al. High School Diet and Risk of Crohn's Disease and Ulcerative Colitis. *Inflammatory bowel diseases* 2015;21(10):2311-9. doi: 10.1097/mib.0000000000000501 [published Online First: 2015/08/04]
30. Chan SS, Luben R, Olsen A, et al. Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease. *Alimentary pharmacology & therapeutics* 2014;39(8):834-42. doi: 10.1111/apt.12670 [published Online First: 2014/03/13]
31. Chan SSM, Luben R, Olsen A, et al. Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). *The American journal of gastroenterology* 2013;108(4):575. doi: 10.1038/ajg.2012.453
32. Chan SS, Luben R, van Schaik F, et al. Carbohydrate intake in the etiology of Crohn's disease and ulcerative colitis. *Inflammatory bowel diseases* 2014;20(11):2013-21. doi: 10.1097/mib.0000000000000168 [published Online First: 2014/09/30]
33. John S, Luben R, Shrestha SS, et al. Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study. *European journal of gastroenterology & hepatology* 2010;22(5):602-6. doi: 10.1097/MEG.0b013e3283352d05 [published Online First: 2010/03/11]
34. de Silva PS, Luben R, Shrestha SS, et al. Dietary arachidonic and oleic acid intake in ulcerative colitis etiology: a prospective cohort study using 7-day food diaries. *European journal of gastroenterology & hepatology* 2014;26(1):11-8. doi: 10.1097/MEG.0b013e328365c372 [published Online First: 2013/11/13]

- 1
2
3
4 466 35. de Silva PS, Olsen A, Christensen J, et al. An association between dietary arachidonic acid, measured in
5 467 adipose tissue, and ulcerative colitis. *Gastroenterology* 2010;139(6):1912-7. doi:
6 468 10.1053/j.gastro.2010.07.065 [published Online First: 2010/10/19]
7
8 469 36. Hart AR, Luben R, Olsen A, et al. Diet in the aetiology of ulcerative colitis: a European prospective cohort
9 470 study. *Digestion* 2008;77(1):57-64. doi: 10.1159/000121412 [published Online First: 2008/03/20]
10 471
11 472 37. Opstelten JL, Leenders M, Dik VK, et al. Dairy Products, Dietary Calcium, and Risk of Inflammatory
12 473 Bowel Disease: Results From a European Prospective Cohort Investigation. *Inflammatory bowel*
13 474 *diseases* 2016;22(6):1403-11. doi: 10.1097/mib.0000000000000798 [published Online First: 2016/04/28]
14 475
15 476 38. Bordoni A, Danesi F, Dardevet D, et al. Dairy products and inflammation: A review of the clinical
16 477 evidence. *Critical reviews in food science and nutrition* 2017;57(12):2497-525. doi:
17 478 10.1080/10408398.2014.967385 [published Online First: 2015/08/20]
18 479
19 480 39. Lahiri M, Luben RN, Morgan C, et al. Using lifestyle factors to identify individuals at higher risk of
20 481 inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk
21 482 and the Norfolk Arthritis Register--the EPIC-2-NOAR Study). *Annals of the rheumatic diseases*
22 483 2014;73(1):219-26. doi: 10.1136/annrheumdis-2012-202481 [published Online First: 2013/03/19]
23 484
24 485 40. Pattison DJ, Symmons DP, Lunt M, et al. Dietary risk factors for the development of inflammatory
25 486 polyarthritis: evidence for a role of high level of red meat consumption. *Arthritis and rheumatism*
26 487 2004;50(12):3804-12. doi: 10.1002/art.20731 [published Online First: 2004/12/14]
27 488
28 489 41. Lauer K. Multiple sclerosis in relation to meat preservation in France and Switzerland. *Neuroepidemiology*
29 490 1989;8(6):308-15. doi: 10.1159/000110199 [published Online First: 1989/01/01]
30 491
31 492 42. Lauer K. The food pattern in geographical relation to the risk of multiple sclerosis in the Mediterranean
32 493 and Near East region. *Journal of epidemiology and community health* 1991;45(3):251-2. [published Online
33 494 First: 1991/09/01]
34 495
35 496 43. Lauer K. Notes on the epidemiology of multiple sclerosis, with special reference to dietary habits.
36 497 *International journal of molecular sciences* 2014;15(3):3533-45. doi: 10.3390/ijms15033533 [published
37 498 Online First: 2014/03/01]
38 499
39 500 44. Lauer K. The history of nitrite in human nutrition: a contribution from German cookery books. *Journal of*
40 501 *clinical epidemiology* 1991;44(3):261-4. [published Online First: 1991/01/01]
41 502
42 503 45. Sharif K, Watad A, Bragazzi NL, et al. Physical activity and autoimmune diseases: Get moving and
43 504 manage the disease. *Autoimmunity reviews* 2018;17(1):53-72. doi: 10.1016/j.autrev.2017.11.010
44 505 [published Online First: 2017/11/08]
45 506
46 507 46. Jones PD, Kappelman MD, Martin CF, et al. Exercise decreases risk of future active disease in patients
47 508 with inflammatory bowel disease in remission. *Inflammatory bowel diseases* 2015;21(5):1063-71. doi:
48 509 10.1097/mib.0000000000000333 [published Online First: 2015/02/28]
49 510
50 511 47. Bilski J, Mazur-Bialy AI, Wierdak M, et al. The impact of physical activity and nutrition on inflammatory
51 512 bowel disease: the potential role of cross talk between adipose tissue and skeletal muscle. *Journal of*
52 513 *physiology and pharmacology : an official journal of the Polish Physiological Society* 2013;64(2):143-55.
53 514 [published Online First: 2013/06/13]
54 515
55 516 48. Wolk K, Mallbris L, Larsson P, et al. Excessive body weight and smoking associates with a high risk of
56 517 onset of plaque psoriasis. *Acta dermato-venereologica* 2009;89(5):492-7. doi: 10.2340/00015555-0711
57 518 [published Online First: 2009/09/08]
58 519
59 520 49. Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. *Scandinavian journal of*
60 521 *rheumatology* 2006;35(3):169-74. doi: 10.1080/03009740600718080 [published Online First: 2006/06/13]
522 523
524 525 50. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. *Mayo*
526 527 *Clinic proceedings* 2006;81(11):1462-71. doi: 10.4065/81.11.1462
528 529
530 531 51. Klareskog L, Malmstrom V, Lundberg K, et al. Smoking, citrullination and genetic variability in the
532 533 immunopathogenesis of rheumatoid arthritis. *Seminars in immunology* 2011;23(2):92-8. doi:
534 535 10.1016/j.smim.2011.01.014 [published Online First: 2011/03/08]
536 537
538
539
540

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

52. Li W, Han J, Choi HK, et al. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. *American journal of epidemiology* 2012;175(5):402-13. doi: 10.1093/aje/kwr325 [published Online First: 2012/01/17]
53. Costenbader KH, Feskanich D, Mandl LA, et al. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. *The American journal of medicine* 2006;119(6):503.e1-9. doi: 10.1016/j.amjmed.2005.09.053 [published Online First: 2006/06/06]
54. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. *The American journal of medicine* 2007;120(11):953-9. doi: 10.1016/j.amjmed.2007.06.020 [published Online First: 2007/11/03]
55. Alfredsson L, Olsson T. Lifestyle and Environmental Factors in Multiple Sclerosis. *Cold Spring Harbor perspectives in medicine* 2018 doi: 10.1101/cshperspect.a028944 [published Online First: 2018/05/08]
56. Palacios N, Alonso A, Bronnum-Hansen H, et al. Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence. *Annals of epidemiology* 2011;21(7):536-42. doi: 10.1016/j.annepidem.2011.03.001 [published Online First: 2011/05/10]
57. Swanson GR, Sedghi S, Farhadi A, et al. Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. *Alcohol (Fayetteville, NY)* 2010;44(3):223-8. doi: 10.1016/j.alcohol.2009.10.019 [published Online First: 2010/08/05]
58. Khasawneh M, Spence AD, Addley J, et al. The role of smoking and alcohol behaviour in the management of inflammatory bowel disease. *Best practice & research Clinical gastroenterology* 2017;31(5):553-59. doi: 10.1016/j.bpg.2017.10.004 [published Online First: 2017/12/03]
59. Abdollahpour I, Nedjat S, Mansournia MA, et al. Lifestyle factors and multiple sclerosis: A population-based incident case-control study. *Multiple sclerosis and related disorders* 2018;22:128-33. doi: 10.1016/j.msard.2018.03.022 [published Online First: 2018/04/21]
60. Kelly KR, Haus JM, Solomon TPJ, et al. A Low-Glycemic Index Diet and Exercise Intervention Reduces TNF[alpha] in Isolated Mononuclear Cells of Older, Obese Adults^{1,2}. *The Journal of Nutrition* 2011;141(6):1089.
61. Andersen V, Hansen AK, Heitmann BL. Potential Impact of Diet on Treatment Effect from Anti-TNF Drugs in Inflammatory Bowel Disease. *Nutrients* 2017;9(3) doi: 10.3390/nu9030286 [published Online First: 2017/03/16]
62. Vieira AT, Castelo PM, Ribeiro DA, et al. Influence of Oral and Gut Microbiota in the Health of Menopausal Women. *Frontiers in Microbiology* 2017;8 doi: 10.3389/fmicb.2017.01884
63. Tjonneland A, Olsen A, Boll K, et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. *Scandinavian journal of public health* 2007;35(4):432-41. doi: 10.1080/14034940601047986 [published Online First: 2007/09/06]
64. Larsen L, Jensen M, Larsen MD, et al. The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease. *Clinical Epidemiology* 2016;8:607-12. doi: 10.2147/CLEP.S99478
65. Wurtz AM, Hansen MD, Tjonneland A, et al. Substitution of meat and fish with vegetables or potatoes and risk of myocardial infarction. *Br J Nutr* 2016;116(9):1602-10. doi: 10.1017/s0007114516003500 [published Online First: 2016/10/25]
66. Sorensen M, Autrup H, Olsen A, et al. Prospective study of NAT1 and NAT2 polymorphisms, tobacco smoking and meat consumption and risk of colorectal cancer. *Cancer Lett* 2008;266(2):186-93. doi: 10.1016/j.canlet.2008.02.046 [published Online First: 2008/03/29]
67. Egeberg R, Olsen A, Christensen J, et al. Associations between red meat and risks for colon and rectal cancer depend on the type of red meat consumed. *J Nutr* 2013;143(4):464-72. doi: 10.3945/jn.112.168799 [published Online First: 2013/02/22]
68. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *Journal of Chronic Diseases* 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8

- 1
2
3
4 563 69. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for
5 564 risk adjustment in hospital discharge abstracts using data from 6 countries. *American journal of*
6 565 *epidemiology* 2011;173(6):676-82. doi: 10.1093/aje/kwq433
7 566
8 566 70. Stata Statistical Software [program]. 15 version, 2017.
9 567
10 568 71. Mason K, Thygesen LC, Stenager E, et al. Evaluating the use and limitations of the Danish National
11 569 Patient Register in register-based research using an example of multiple sclerosis. *Acta neurologica*
12 570 *Scandinavica* 2012;125(3):213-7. doi: 10.1111/j.1600-0404.2011.01558.x [published Online First:
13 571 2011/06/28]
14 572 72. Lophaven SN, Lynge E, Burisch J. The incidence of inflammatory bowel disease in Denmark 1980-2013: a
15 572 nationwide cohort study. *Alimentary pharmacology & therapeutics* 2017;45(7):961-72. doi:
16 573 10.1111/apt.13971 [published Online First: 2017/02/24]
17 574 73. Kingwell E, Marriott JJ, Jetté N, et al. Incidence and prevalence of multiple sclerosis in Europe: a
18 575 systematic review. *BMC neurology* 2013;13(1):128. doi: 10.1186/1471-2377-13-128
19 576 74. Bentzen J, Meulengracht Flachs E, Stenager E, et al. Prevalence of multiple sclerosis in Denmark 1950—
20 577 2005. *Multiple Sclerosis Journal* 2010;16(5):520-25. doi: 10.1177/1352458510364197
21 578 75. Koch-Henriksen N, Magyari M, Laursen B. Registers of multiple sclerosis in Denmark. *Acta neurologica*
22 579 *Scandinavica* 2015;132(199):4-10. doi: 10.1111/ane.12424 [published Online First: 2015/06/06]
23 580 76. Society TDMS. Fakta om sclerose 2013 [Available from: [https://scleroseforeningen.dk/viden-og-nyt/hvad-](https://scleroseforeningen.dk/viden-og-nyt/hvad-er-sclerose/fa-alle-tallene-om-sclerose)
24 581 [er-sclerose/fa-alle-tallene-om-sclerose](https://scleroseforeningen.dk/viden-og-nyt/hvad-er-sclerose/fa-alle-tallene-om-sclerose) accessed May 2018.
25 581
26 582 77. Kiadaliri AA, Kristensen LE, Englund M. Burden of rheumatoid arthritis in the Nordic region, 1990-2015:
27 583 a comparative analysis using the Global Burden of Disease Study 2015. *Scandinavian journal of*
28 584 *rheumatology* 2018;47(2):1-101. doi: 10.1080/03009742.2017.1314002 [published Online First:
29 585 2017/08/03]
30 586 78. Pedersen JK, Svendsen AJ, Horslev-Petersen K. Incidence of Rheumatoid Arthritis in the Southern part of
31 587 Denmark from 1995 to 2001. *The open rheumatology journal* 2007;1:18-23. doi:
32 588 10.2174/1874312900701010018 [published Online First: 2007/01/01]
33 588
34 589 79. Pedersen CB. The Danish Civil Registration System. *Scandinavian Journal of Public Health*
35 590 2011;39(7_suppl):22-25. doi: 10.1177/1403494810387965
36 591 80. Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient Registry: a review of content,
37 592 data quality, and research potential. *Clinical epidemiology* 2015;7:449-90. doi: 10.2147/CLEP.S91125
38 593 81. Pottgård A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data Resource Profile: The Danish National
39 594 Prescription Registry. *International Journal of Epidemiology* 2016;dyw213. doi: 10.1093/ije/dyw213
40 595 82. Helweg-Larsen K. The Danish Register of Causes of Death. *Scandinavian Journal of Public Health*
41 596 2011;39(7_suppl):26-29. doi: 10.1177/1403494811399958
42 596
43 597 83. Ibfelt EH, Sorensen J, Jensen DV, et al. Validity and completeness of rheumatoid arthritis diagnoses in the
44 598 nationwide DANBIO clinical register and the Danish National Patient Registry. *Clin Epidemiol*
45 599 2017;9:627-32. doi: 10.2147/lep.S141438 [published Online First: 2017/12/15]
46 600 84. Lindhardsen J, Gislason GH, Jacobsen S, et al. Non-steroidal anti-inflammatory drugs and risk of
47 601 cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. *Annals of the*
48 602 *rheumatic diseases* 2014;73(8):1515-21. doi: 10.1136/annrheumdis-2012-203137 [published Online First:
49 603 2013/06/12]
50 604 85. European prospective investigation into cancer and nutrition E. EPIC Study 2014 [Available from:
51 605 <http://epic.iarc.fr/> accessed March 2018.
52 605
53 606 86. Racine A, Carbonnel F, Chan SS, et al. Dietary Patterns and Risk of Inflammatory Bowel Disease in
54 607 Europe: Results from the EPIC Study. *Inflammatory bowel diseases* 2016;22(2):345-54. doi:
55 608 10.1097/mib.0000000000000638 [published Online First: 2015/12/31]
56 609 87. Togo P, Heitmann BL, Sorensen TI, et al. Consistency of food intake factors by different dietary
57 610 assessment methods and population groups. *The British journal of nutrition* 2003;90(3):667-78.
58 611 [published Online First: 2003/09/18]
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

88. Tjonneland A, Overvad K, Haraldsdottir J, et al. Validation of a semiquantitative food frequency questionnaire developed in Denmark. *IntJ Epidemiol* 1991;20(4):906-12.
89. Osler M, Heitmann BL. The validity of a short food frequency questionnaire and its ability to measure changes in food intake: a longitudinal study. *International journal of epidemiology* 1996;25(5):1023-9. [published Online First: 1996/10/01]
90. Koster-Rasmussen R, Siersma V, Halldorsson TI, et al. Missing portion sizes in FFQ--alternatives to use of standard portions. *Public health nutrition* 2015;18(11):1914-21. doi: 10.1017/s1368980014002389 [published Online First: 2014/11/11]
91. Tjonneland A, Haraldsdottir J, Overvad K, et al. Influence of individually estimated portion size data on the validity of a semiquantitative food frequency questionnaire. *IntJ Epidemiol* 1992;21(4):770-77.
92. Feskanich D, Rimm EB, Giovannucci EL, et al. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. *Journal of the American Dietetic Association* 1993;93(7):790-6. [published Online First: 1993/07/01]
93. Hunter DJ, Sampson L, Stampfer MJ, et al. Variability in portion sizes of commonly consumed foods among a population of women in the United States. *American journal of epidemiology* 1988;127(6):1240-9. [published Online First: 1988/06/01]
94. Andersen V, Chan S, Luben R, et al. Fibre intake and the development of inflammatory bowel disease : A European prospective multi-centre cohort study (EPIC-IBD). *Journal of Crohn's and Colitis* 2018;12(2):129.
95. Goldbohm RA, van 't Veer P, van den Brandt PA, et al. Reproducibility of a food frequency questionnaire and stability of dietary habits determined from five annually repeated measurements. *European journal of clinical nutrition* 1995;49(6):420-9. [published Online First: 1995/06/01]
96. Johnsen NF, Christensen J, Thomsen BL, et al. Physical Activity and Risk of Colon Cancer in a Cohort of Danish Middle-Aged Men and Women. *European Journal of Epidemiology* 2006;21(12):877-84. doi: 10.1007/s10654-006-9076-z
97. uk biobank. Improving the health of future generations [Available from: <http://www.ukbiobank.ac.uk/> accessed May 2018.
98. Andersen V, Vogel U. Dietary fibres and meat in relation to Colorectal Cancer. *Norske Gastroenterologisk Forening-nytt* 2014(21):34-36.
99. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. *Nature* 2012;487(7405):104-8. doi: 10.1038/nature11225 [published Online First: 2012/06/23]
100. Strober W. Vitamin A rewrites the ABCs of oral tolerance. *Mucosal immunology* 2008;1(2):92-5. doi: 10.1038/mi.2007.22 [published Online First: 2008/12/17]
101. Agmon-Levin N, Theodor E, Segal RM, et al. Vitamin D in systemic and organ-specific autoimmune diseases. *Clinical reviews in allergy & immunology* 2013;45(2):256-66. doi: 10.1007/s12016-012-8342-y [published Online First: 2012/12/15]
102. Kaulmann A, Bohn T. Carotenoids, inflammation, and oxidative stress--implications of cellular signaling pathways and relation to chronic disease prevention. *Nutrition research (New York, NY)* 2014;34(11):907-29. doi: 10.1016/j.nutres.2014.07.010 [published Online First: 2014/08/20]
103. Ejsing-Duun M, Josephsen J, Aasted B, et al. Dietary gluten reduces the number of intestinal regulatory T cells in mice. *Scandinavian journal of immunology* 2008;67(6):553-9. doi: 10.1111/j.1365-3083.2008.02104.x [published Online First: 2008/05/15]
104. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. *Nature reviews Immunology* 2011;11(2):119-30. doi: 10.1038/nri2916 [published Online First: 2011/01/27]
105. Pedros C, Duguet F, Saoudi A, et al. Disrupted regulatory T cell homeostasis in inflammatory bowel diseases. *World journal of gastroenterology* 2016;22(3):974-95. doi: 10.3748/wjg.v22.i3.974 [published Online First: 2016/01/27]

- 1
2
3
4 660 106. Yao CK, Muir JG, Gibson PR. Review article: insights into colonic protein fermentation, its modulation
5 661 and potential health implications. *Alimentary pharmacology & therapeutics* 2016;43(2):181-96. doi:
6 662 10.1111/apt.13456 [published Online First: 2015/11/04]
7
8 663 107. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. *Nature reviews Immunology*
9 664 2016;16(6):341-52. doi: 10.1038/nri.2016.42 [published Online First: 2016/05/28]
10 665 108. Desai MS, Seekatz AM, Koropatkin NM, et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the
11 666 Colonic Mucus Barrier and Enhances Pathogen Susceptibility. *Cell* 2016;167(5):1339-53.e21. doi:
12 667 10.1016/j.cell.2016.10.043 [published Online First: 2016/11/20]
13 668 109. Png CW, Linden SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa
14 669 augment in vitro utilization of mucin by other bacteria. *Am J Gastroenterol* 2010;105(11):2420-8. doi:
15 670 10.1038/ajg.2010.281 [published Online First: 2010/07/22]
16 671 110. Windey K, De Preter V, Louat T, et al. Modulation of protein fermentation does not affect fecal water
17 672 toxicity: a randomized cross-over study in healthy subjects. *PloS one* 2012;7(12):e52387. doi:
18 673 10.1371/journal.pone.0052387
19 674 111. Ijssennagger N, van der Meer R, van Mil SWC. Sulfide as a Mucus Barrier-Breaker in Inflammatory
20 675 Bowel Disease? *Trends in Molecular Medicine* 2016;22(3):190-99. doi: 10.1016/j.molmed.2016.01.002
21 676 112. Gibson GR, Macfarlane GT, Cummings JH. Sulphate reducing bacteria and hydrogen metabolism in the
22 677 human large intestine. *Gut* 1993;34(4):437-39. doi: 10.1136/gut.34.4.437
23 678 113. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature*
24 679 2011;474(7351):298-306. doi: 10.1038/nature10208
25 680 114. Cui J, Chen Y, Wang HY, et al. Mechanisms and pathways of innate immune activation and regulation
26 681 in health and cancer. *Human Vaccines & Immunotherapeutics* 2014;10(11):3270-85. doi:
27 682 10.4161/21645515.2014.979640
28 683 115. Jia W, Whitehead RN, Griffiths L, et al. Diversity and distribution of sulphate-reducing bacteria in
29 684 human faeces from healthy subjects and patients with inflammatory bowel disease. *FEMS*
30 685 *Immunology & Medical Microbiology* 2012;65(1):55-68. doi: 10.1111/j.1574-695X.2012.00935.x
31
32
33
34 686
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Hypothesis for effects of diet in relation to development of chronic inflammatory diseases (CIDs) "Diet (meat⁹⁸, fibre⁹⁸, animal fat⁹⁹, n-3³⁰ and n-6 polyunsaturated fatty acids, vitamin A¹⁰⁰ and D¹⁰¹, carotenoids¹⁰², smoking, gluten¹⁰³) may affect the immune system¹⁰⁴ ¹⁰⁵ either directly or indirectly via e.g. the activity and composition of the gut microbiome.¹⁰⁶ ¹⁰⁷ The effect of low intake of fiber/high intake of red and processed meat is shown at left: In short, low intake of fibre (which could otherwise serve as a nutrient for the microbes) may lead to the microbial metabolism of mucus and to decrease of the intestinal mucus layer.⁶¹ ¹⁰⁸ ¹⁰⁹ A high intake of red and processed meat may render the mucus layer penetrable to e.g. bacteria by reducing the disulphide bonds in the mucus network.⁸ ¹⁰⁶ ¹¹⁰ Thus, microbes may reach the epithelium⁸ ¹¹¹ ¹¹² and activate the immune system.⁸ ¹¹³ ¹¹⁴ There is some support for such a mechanism in chronic inflammatory diseases (CIDs)⁸, including findings of; high amounts of sulphate-reducing bacteria in inflammatory bowel disease (IBD) patients;⁸ ¹¹² ¹¹⁵ association of high fibre intake with low risk of IBD among 170 776 participants from the prospective Nurses' Health Study I⁸ ²⁷; and association of high intake of red meat and total protein and risk of developing inflammatory polyarthritis in the population-based prospective cohort of 25 630 participants from the European Prospective Investigation of Cancer in Norfolk.⁸ ³⁹ ⁴⁰"Note. Figure from "Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine," by Christensen R, Heitmann BL, Andersen KW, et al., *BMJ Open* 2018;⁸:e018166. doi: 10.1136/bmjopen-2017-018166. Available at: <http://bmjopen.bmj.com/content/8/2/e018166>. Copyright 2018 by Vibeke Andersen.

108x73mm (300 x 300 DPI)